0270-9139/89/0906-0914$02.00/0
HEPATOLOGY
Copyright © 1989 by The American Association for the Study of Liver Diseases
Vol. 9, No. 6, pp. 914–920, 1989
Printed in U.S.A.

Subject Index to Volume 9

Abdomen, symptoms and gallstone disease, 856
Acetaldehyde
  covalent binding to liver tubulin, 161
  preferential covalent binding, α-chain, rat liver tubulin, 57
Acinus
  heterogeneity of fatty acid binding protein expression, clofibrate-treated rats, 12
  location of hemopoietic colonies, postnatal and phenylhydrazine-treated adult mice, 29
Acupuncture, epidemic HBV hepatitis, HEPATOLOGY *Elsewhere*, 509
Adrenergic fibers, localization of tyrosine-containing nerves, mammalian liver, 839
Aging
  determinants and, hepatic drug clearance, 331
  liver volume and apparent liver blood flow, healthy persons, 297
Albumin, HBsAg binding, cross-linking by transglutaminase, 726
Alcohol
  detection of alcoholic hepatitis, procollagen peptide, laminin, 693
  -fed rats, high-density lipoprotein particles, apolipoprotein E deficiency, 307
Alcoholic liver disease
  aggravating factor, endotoxin-induced hypercoagulability, 846
  animal models, HEPATOLOGY *Elsewhere*, 904
  fibrosis, changes, liver and spleen volume, 589
  hepatic aldehyde dehydrogenase activity, 704
  hepatitis B virus, with hepatocellular carcinoma, 514
  liver and IgA, implications, 763
  tumor necrosis factor, acute phase response, pathogenesis, 497
Alcoholism, ethanol-induced centrilobular hypoxia, necrosis, 302
Aldehyde dehydrogenase, hepatic activity, alcoholic liver disease, 704
Allografts
  chronically rejected, histometric analysis, 204
  renal, stable recipients, impaired liver function, 606
Amino acids
  hepatic encephalopathy, thioacetamide liver failure, 594
  hepatitis A virus, insights from molecular biology, 889
  metabolism, vitamin B_6 repletion, cirrhosis, 582
  transport, digitonin/collagenase perfusion, periportal and perivenous hepatocytes, 22
Aminopyrine breath test, after liver transplantation, outcome, 602
Aminotransferase
  amiodarone hepatotoxicity, 679
  chronic elevations, mild to moderate degree, asymptomatic patients, 193
  serum titers of pre-S(2) antigen, acute and chronic type B hepatitis, 175
Amiodarone, hepatotoxicity, 679
Ammonia, -metabolizing enzymes, localization, human liver, 367
Androgen
  effect on hepatoma growth rate, 621
  prostatic hypertrophy, elderly cirrhotic patient, HEPATOLOGY *Elsewhere*, 167
  receptor, hepatocellular carcinoma, HEPATOLOGY *Elsewhere*, 509
Angioplasty, laser-assisted, inferior vena caval obstructions, HEPATOLOGY *Elsewhere*, 338
Animal models, alcoholic liver disease, HEPATOLOGY *Elsewhere*, 904
Anions, organic, nuclear hepatology progress, 139
Anoxia, hepatocyte injury, 219
Antibiotics, polymorphonuclear cell count, spontaneous bacterial peritonitis, 423
Anti-HBc, serum negativity, HBsAg carrier infants, 102
Apolipoprotein E, deficiency, lipoprotein particles, alcohol-fed rats, 307
Ascites
  Chlamydia trachomatis and, HEPATOLOGY *Elsewhere*, 505
  promotion of formation by vasodilatation, portal hypertension, 797, 798
Ascitic fluid, culture technique, 662
Assays
  detection of anti-liver cell membrane antibody, hepatocellular carcinoma, 210
  multiple-indicator dilution technique, normal and retrograde flow, rat liver perfusions, 285
Atrial natriuretic factor, renin-aldosterone and, volume regulation, cirrhosis, 417
Autoantibodies
  antimitochondrial, reactivity of sera, primary biliary cirrhosis, 63
  liver diseases and, nuclear envelope components, 911
Autoimmune diseases, C4 function, autoimmune chronic active hepatitis, 345
Autoimmunity, immune mechanisms, primary sclerosing cholangitis, childhood, 198

Bile
  gallbladder, cholesterol nucleation-promoting activity, HEPATOLOGY *Elsewhere*, 507
  hepatic metabolism, colloidal gold-low-density lipoprotein complexes, 380
  metabolism of D-glucaro-1,4-lactone, 552
  transcellular access, horseradish peroxidase, molecular charge effect, 866
Bile acid
  benign recurrent intrahepatic cholestasis, long-term follow-up study, 532
  metabolism in human hyperthyroidism, 852
  monohydroxylated, permeabilization, endoplasmic reticulum, 663, 665
  nordeoxycholate side chain conjugates, hepatobiliary transport, canalicular transport defect, 861
Bile duct
  chronically rejected human liver allografts, histometric analysis, 204
  common stones, treatment, laser lithotripsy, 792
  epithelial cells, enzyme profile, hepatocarcinogenesis, 477
Biliary enteroenterostomy, effect on pharmacokinetics, cyclosporine, 393
Bilirubin
  hepatic handling of, thyroid hormones, 314
  hepatobiliary transport, nordeoxycholate side chain conjugates, 861
Biopsy, diagnosis with new morphological criteria, well-differentiated hepatocellular carcinoma, 751
Blacks, South African, membranous obstruction, hepatocellular carcinoma, 121
β-Blockers, prevention of recurrent bleeding, alcoholic cirrhosis, 433
Blood
  coagulation factors, liver transplantation, 710
  hemodynamic effects of volume restitution, portal hypertension,

0270-9139/89/0906-0914$02.00/0
HEPATOLOGY
Copyright © 1989 by The American Association for the Study of Liver Diseases
Vol. 9, No. 6, pp. 914–920, 1989
Printed in U.S.A.

Subject Index to Volume 9

Abdomen, symptoms and gallstone disease, 856
Acetaldehyde
  covalent binding to liver tubulin, 161
  preferential covalent binding, α-chain, rat liver tubulin, 57
Acinus
  heterogeneity of fatty acid binding protein expression, clofibrate-treated rats, 12
  location of hemopoietic colonies, postnatal and phenylhydrazine-treated adult mice, 29
Acupuncture, epidemic HBV hepatitis, HEPATOLOGY *Elsewhere*, 509
Adrenergic fibers, localization of tyrosine-containing nerves, mammalian liver, 839
Aging
  determinants and, hepatic drug clearance, 331
  liver volume and apparent liver blood flow, healthy persons, 297
Albumin, HBsAg binding, cross-linking by transglutaminase, 726
Alcohol
  detection of alcoholic hepatitis, procollagen peptide, laminin, 693
  -fed rats, high-density lipoprotein particles, apolipoprotein E deficiency, 307
Alcoholic liver disease
  aggravating factor, endotoxin-induced hypercoagulability, 846
  animal models, HEPATOLOGY *Elsewhere*, 904
  fibrosis, changes, liver and spleen volume, 589
  hepatic aldehyde dehydrogenase activity, 704
  hepatitis B virus, with hepatocellular carcinoma, 514
  liver and IgA, implications, 763
  tumor necrosis factor, acute phase response, pathogenesis, 497
Alcoholism, ethanol-induced centrilobular hypoxia, necrosis, 302
Aldehyde dehydrogenase, hepatic activity, alcoholic liver disease, 704
Allografts
  chronically rejected, histometric analysis, 204
  renal, stable recipients, impaired liver function, 606
Amino acids
  hepatic encephalopathy, thioacetamide liver failure, 594
  hepatitis A virus, insights from molecular biology, 889
  metabolism, vitamin B_6 repletion, cirrhosis, 582
  transport, digitonin/collagenase perfusion, periportal and perivenous hepatocytes, 22
Aminopyrine breath test, after liver transplantation, outcome, 602
Aminotransferase
  amiodarone hepatotoxicity, 679
  chronic elevations, mild to moderate degree, asymptomatic patients, 193
  serum titers of pre-S(2) antigen, acute and chronic type B hepatitis, 175
Amiodarone, hepatotoxicity, 679
Ammonia, -metabolizing enzymes, localization, human liver, 367
Androgen
  effect on hepatoma growth rate, 621
  prostatic hypertrophy, elderly cirrhotic patient, HEPATOLOGY *Elsewhere*, 167
  receptor, hepatocellular carcinoma, HEPATOLOGY *Elsewhere*, 509
Angioplasty, laser-assisted, inferior vena caval obstructions, HEPATOLOGY *Elsewhere*, 338
Animal models, alcoholic liver disease, HEPATOLOGY *Elsewhere*, 904
Anions, organic, nuclear hepatology progress, 139
Anoxia, hepatocyte injury, 219
Antibiotics, polymorphonuclear cell count, spontaneous bacterial peritonitis, 423
Anti-HBc, serum negativity, HBsAg carrier infants, 102
Apolipoprotein E, deficiency, lipoprotein particles, alcohol-fed rats, 307
Ascites
  Chlamydia trachomatis and, HEPATOLOGY *Elsewhere*, 505
  promotion of formation by vasodilatation, portal hypertension, 797, 798
Ascitic fluid, culture technique, 662
Assays
  detection of anti-liver cell membrane antibody, hepatocellular carcinoma, 210
  multiple-indicator dilution technique, normal and retrograde flow, rat liver perfusions, 285
Atrial natriuretic factor, renin-aldosterone and, volume regulation, cirrhosis, 417
Autoantibodies
  antimitochondrial, reactivity of sera, primary biliary cirrhosis, 63
  liver diseases and, nuclear envelope components, 911
Autoimmune diseases, C4 function, autoimmune chronic active hepatitis, 345
Autoimmunity, immune mechanisms, primary sclerosing cholangitis, childhood, 198

Bile
  gallbladder, cholesterol nucleation-promoting activity, HEPATOLOGY *Elsewhere*, 507
  hepatic metabolism, colloidal gold-low-density lipoprotein complexes, 380
  metabolism of D-glucaro-1,4-lactone, 552
  transcellular access, horseradish peroxidase, molecular charge effect, 866
Bile acid
  benign recurrent intrahepatic cholestasis, long-term follow-up study, 532
  metabolism in human hyperthyroidism, 852
  monohydroxylated, permeabilization, endoplasmic reticulum, 663, 665
  nordeoxycholate side chain conjugates, hepatobiliary transport, canalicular transport defect, 861
Bile duct
  chronically rejected human liver allografts, histometric analysis, 204
  common stones, treatment, laser lithotripsy, 792
  epithelial cells, enzyme profile, hepatocarcinogenesis, 477
Biliary enteroenterostomy, effect on pharmacokinetics, cyclosporine, 393
Bilirubin
  hepatic handling of, thyroid hormones, 314
  hepatobiliary transport, nordeoxycholate side chain conjugates, 861
Biopsy, diagnosis with new morphological criteria, well-differentiated hepatocellular carcinoma, 751
Blacks, South African, membranous obstruction, hepatocellular carcinoma, 121
β-Blockers, prevention of recurrent bleeding, alcoholic cirrhosis, 433
Blood
  coagulation factors, liver transplantation, 710
  hemodynamic effects of volume restitution, portal hypertension,

cirrhosis, 808
human hepatocyte growth factor, clinical significance, fulminant hepatic failure, 875
screening, assessment, posttransfusion non-A/non-B hepatitis, 449
Blood flow
cerebral, propranolol, cirrhosis, 439
liver volume and, effect of aging, healthy persons, 297
Bone, disease, chronic childhood cholestasis, 258
Bone marrow, transplantation, nodular regenerative hyperplasia, 443
Book Reviews, 169, 341, 512, 659, 794, 908

Calcium, dietary, gentamicin nephrotoxicity, dietary calcium, 519
Calcium channel blockers, vasodilator therapy of portal hypertension, 896
Cancer, liver, immunotargeting, 646
Carbamoylphosphate synthetase, ammonia-metabolizing enzymes, localization, human liver, 367
Carbon tetrachloride
alterations in functional receptor expression, cirrhotic rat hepatocytes, 6
cirrhosis, urea cycle enzyme activities, 373
-induced lipid peroxidation, iloprost effect, hepatoprotection, 830
Carcinoma, hepatocellular
androgen receptors and, HEPATOLOGY *Elsewhere*, 509
biochemical aspects, α-L-fucosidase, 249
curative resection, patterns, intrahepatic recurrence, 457
defective function, LAK cells, natural killer cells, 471
detection of antibody, liver cell membrane antigens, 210
α-fetoprotein monitoring, chronic hepatitis B virus, Chinese patients, 110
HBsAg-positive patients, detection, HBsAg and HBcAg in liver and tumor, 747
hepatitis B virus, alcoholic liver disease, 514
immunolocalization, tumor-associated antigens, 625
immunotargeting, 646
monoclonal antibody against α-fetoprotein, radioimmunodetection, 116
progressive development, poly(A⁺)RNA levels, 756
resected, morphological and histological features, cirrhotic patients, 253
role of membranous obstruction, inferior vena cava, South African Blacks, 121
targeted therapy, HEPATOLOGY *Elsewhere*, 657
well-differentiated, biopsy diagnosis, new morphological criteria, 751
woodchuck hepatitis virus-infected woodchucks, 461
Cell culture, technique, ascitic fluid, 662
Chlamydia trachomatis, ascites and, HEPATOLOGY *Elsewhere*, 505
Cholangiopathy, ischemic, floxuridine-induced sclerosing cholangitis, 215
Cholecystolithiasis, incidence, patients with chronic liver disease, 538
Cholestasis
benign recurrent intrahepatic, long-term follow-up study, 532
chronic childhood, bone disease, 258
extrahepatic, gentamicin nephrotoxicity, dietary calcium, 519
vitamin E deficiency, primary biliary cirrhosis, 525
Cholesterol
crystals, phospholipid vesicles, gallbladder bile, 541
nucleation-promoting activity, gallbladder bile, HEPATOLOGY *Elsewhere*, 505
reduced binding and removal of chylomicron remnants, ethionine-induced premalignant liver, 731
regulation of metabolism, low- and high-density lipoproteins, HepG2 cells, 547
Chylomicron, reduced binding and removal of remnants, ethionine-induced premalignant liver, 731
Cirrhosis
alcoholic
additive effect, ketanserin/verapamil/propranolol, 83
prevention of recurrent bleeding, β-blockers, 433
animal models, 500
carbon tetrachloride, urea cycle enzyme activities, 373
cerebral blood flow, propranolol, 439
colchicine treatment, HEPATOLOGY *Elsewhere*, 655, 656
effect of vasodilators, hepatic microcirculation, 820
elderly patient, prostatic hypertrophy, HEPATOLOGY *Elsewhere*, 167
gluconeogenesis from nitrogen precursors, hyperammonemia, 343
hemodynamic effects of blood volume restitution, portal hypertension, 808
initial hemorrhage, esophageal varices, HEPATOLOGY *Elsewhere*, 905
oxygen transport and uptake, effects, vasoactive drugs, 427
rat hepatocytes, alterations, functional receptor expression, 6
resected hepatocellular carcinoma, morphological and histological features, 253
unrestrained dogs, serotonin blockade, portal hypertension, 265
variceal bleeding
analysis of survival, rebleeding, 801
vitamin B_6 repletion pyridoxine, amino acid metabolism, 582
volume regulation, atrial natriuretic factor, renin-aldosterone, 417
Clofibrate, -treated rats, acinar heterogeneity, fatty acid binding protein, 12
Clonidine, effect on hepatic microcirculation, cirrhosis, 820
Coagulation, factors in liver transplantation, 710
Colchicine, treatment of cirrhosis, HEPATOLOGY *Elsewhere*, 655, 656
Collagen
connective tissue matrix constituents, dynamics during infection, *Schistosoma mansoni*, 50
proline-incorporating cells, chronic active liver disease, 37
Collagenase, perfusion, amino acid transport, periportal and perivenous hepatocytes, 22
Colloidal gold, -low-density lipoprotein complexes, hepatic metabolism, 380
Complements, C4 function, autoimmune chronic active hepatitis, 345
Correspondence
Anwer, Engelking, and Lester: Reply, 665
Bréchot: To the Editor, 514
Combettes, Berthon, and Claret: To the Editor, 663
Harrison: Reply, 515
HEPATOLOGY *Elsewhere*: *see* HEPATOLOGY *Elsewhere* Correspondence
Kabadi: Reply, 344
Kalser: To the Editor, 796
Lassoued, Danon, André, Courvalin, and Dhumeaux: To the Editor, 911
Lozano, Parés, Borche, Plana, Gallart, Rodés, and Vives: Reply, 911
Runyon: Reply, 662
Sainz, Soriano, Guarner, Coll and Vilardell: To the Editor, 662
Schrier: Reply, 798
Senaldi, Mieli-Vergani, Mowat, and Vergani: To the Editor, 345
Sherman: To the Editor, 514
Thornton and Losowsky: To the Editor, 797
Trevisani, Bernardi, and Gasbarrini: To the Editor, 343
Cyclosporin A, suppressive effects, murine schistosomiasis, 339
Cyclosporine, effect on pharmacokinetics, biliary enteroenterostomy, 393
Cytoskeleton, organization and functional changes, monocytes, chronic hepatitis B, 720

Dacarbazine, hepatic vascular toxicity, HEPATOLOGY *Elsewhere*, 790
Dentists, protection against HBV transmission, HEPATOLOGY *Elsewhere*, 902
Desmin, fat-storing cells and myofibroblasts, HEPATOLOGY *Elsewhere*, 903

Dextran, fluorescein isothiocyanate transport, quantitative study, rat liver, 75
Diazoxide, effect on hepatic microcirculation, cirrhosis, 820
Diet
high-protein, urea cycle enzyme activities, carbon tetrachloride cirrhosis, 373
postprandial portal hemodynamics, chronic liver disease, normal patients, 815
Digitonin, perfusion, amino acid transport, periportal and perivenous hepatocytes, 22
Digoxin, -like immunoreactive substances, chronic liver disease, 363
Dihydrolipoamide acetyltransferase, immunization of experimental animals, mitochondrial antibody generation, 411
Diltiazem, effect on hepatic microcirculation, cirrhosis, 820
DNA
integration, complexities, hepatitis B virus, 514, 515
synthesis, Kupffer cell stimulation, hepatocytes, 405
Drug clearance, aging and, determinants, 331

Editorial
Blei: vasodilator therapy of portal hypertension, 896
Gerber and Thung: pre-S2 region of hepatitis B virus, 328
Gumucio: hepatocyte heterogeneity, 154
Israel: acetaldehyde binding to tubulin, 161
Keegan-Rogers: immunotargeting in liver cancer, 646
Mullen and McCullough: animal models of chronic liver disease, 500
Pohl: drug-induced allergic hepatitis, 785
Sokol: coming of age of vitamin E, 649
Thiele: tumor necrosis factor in alcoholic liver disease, 497
Vestal: aging and determinants of hepatic drug clearance, 331
Electroencephalography, nonspecificity of triphasic waves, HEPATOLOGY *Elsewhere*, 337
Embryotoxicity, pyrrolizidine-containing drugs, HEPATOLOGY *Elsewhere*, 509
Encephalopathy
hepatic
animal models, 500
cerebral blood flow in cirrhosis, propranolol, 439
thioacetamide liver failure, 594
portal-systemic, embolization of shunt, HEPATOLOGY *Elsewhere*, 164
Endoplasmic reticulum
covalently bound metabolites, hepatocyte plasma membrane, isaxonine, 675
selective permeabilization, monohydroxylated bile acids, liver, 663, 665
Endothelial cells, characteristics of fat-storing cells, interaction with viruses, 352
Endotoxins
-induced hypercoagulability, aggravating factor, alcoholic liver disease, 846
low-dose, fibronectin release, liver parenchymal and Kupffer cells, 562
Enzymes, drug-metabolizing, retrograde liver perfusion, 285
Epidermal growth factor, biological effects, gastrointestinal tract and liver, 126
Estradiol, prostatic hypertrophy, elderly cirrhotic patient, HEPATOLOGY *Elsewhere*, 167
Estrogen
effect on hepatocyte proliferation, 614
effect on hepatoma growth rate, 621
Ethanol
covalent binding of acetaldehyde, α-chain, rat liver tubulin, 57
endotoxin-induced hypercoagulability, aggravating factor, alcoholic liver disease, 846
-induced centrilobular hypoxia, necrosis, 302
Ethionine, -induced premalignant liver, reduced binding, chylomicron remnants, 731

Fat-storing cells
interaction with viruses, 352
myofibroblasts and, HEPATOLOGY *Elsewhere*, 903
Fatty acid binding protein, acinar heterogeneity of expression, clofibrate-treated rats, 12
Ferrochelatase, modulation of activity by dietary manipulation, mitochondrial phospholipid fatty acyl groups, 557
α-Fetoprotein
monitoring, chronic hepatitis B virus infection, Chinese patients, 110
monoclonal antibody, radioimmunodetection, hepatocellular carcinoma, 116
Fibronectin, release from liver parenchymal and Kupffer cells, effect, low-dose endotoxin, 562
Fibrosis, alcoholic liver, changes, liver and spleen volume, 589
Floxuridine, -induced sclerosing cholangitis, ischemic cholangiopathy, 215
Fluorescein isothiocyanate, -dextran transport in microcirculation, quantitative study, rat liver, 75
α-L-Fucosidase, biochemical aspects, hepatocellular carcinoma, 249

Gallbladder
bile
cholesterol nucleation-promoting activity, HEPATOLOGY *Elsewhere*, 507
cholesterol-phospholipid vesicles, cholesterol crystals, 541
Gallstone, disease, abdominal symptoms, 856
Gastrointestinal system
biological effects of epidermal growth factor, 126
maintenance of absorptive function, simplified single stage total hepatectomy, 69
Genome, compact organization, hepatitis B virus, 322
Gentamicin, nephrotoxicity, extrahepatic cholestasis, dietary calcium, 519
D-Glucaro-1,4-lactone, excretion in bile and urine, biliary secretion, β-glucuronidase, 552
Gluconeogenesis, nitrogen precursors, hyperammonemia, cirrhosis, 343
β-Glucuronidase, metabolism of D-glucaro-1,4-lactone, 552
Glutathione *S*-transferase
differential regulation, cultured hepatocytes, 235
update, 486
Glycosaminoglycans, connective tissue matrix constitutents, dynamics during infection, *Schistosoma mansoni*, 50
Grant application, statistics on approval of amended applications, 796

HBcAg, assessment of donor blood screening, posttransfusion non-A/non-B hepatitis, 449
HBsAg
binding to serum albumin, cross-linking by transglutaminase, 726
carriers
etiology, acute hepatitis, 452
infants, serum anti-HBc negativity, 102
detection of HBcAg and, HBsAg-positive patients, primary hepatocellular carcinoma, 747
hepatitis B-associated polyarteritis nodosa, epidemiology, Alaskan Eskimos, 97
-positive mothers, immunization of newborns, HEPATOLOGY *Elsewhere*, 900
Heart, amiodarone hepatotoxicity, 679
Heat shock proteins, HSP70, expression, liver and hepatomas, 740
Heme, pathway precursors, pharmacokinetics, tin-mesoporphyrin, 882
Hemochromatosis, hereditary, regulation, hepatic transferrin receptor, 1
Hemodynamics
effects of blood volume restitution, portal hypertension, cirrhosis,

808
long-term effects, ketanserin, portal hypertension, 88
portal, effect of meal, 815
portal pressure and, propranolol, portal hypertensive rats, 269
Hemopoietic cells, location in liver acinus, postnatal and phenylhydrazine-treated adult mice, 29
Hemorrhage, initial, esophageal varices, HEPATOLOGY *Elsewhere*, 905
Hepadnavirus, experimental systems for study, 635
Hepatectomy, total, maintenance, gastrointestinal absorptive function, 69
Hepatitis
acute, etiology of, HBsAg carriers, 452
alcoholic
detection of, procollagen peptide and laminin, 693
tumor necrosis factor production, monocytes, 349
allergic, drug-induced, isaxonine, 785
autoimmune chronic active
C4 function, children, 345
immune mechanisms, childhood, 198
GB, studies of agent, tamarins, 186
immunoallergic, isaxonine, hepatocyte plasma membrane, 675
metoprolol-induced, rate of oxidation, HEPATOLOGY *Elsewhere*, 163
relapsing or reinfectious, lyme disease, HEPATOLOGY *Elsewhere*, 335
Hepatitis A virus, insights from molecular biology, 889
Hepatitis B
acute and chronic
interferon-associated 2′,5′-oligoadenylate synthetase, 105
serum titers, pre-S(2) antigen, 175
-associated polyarteritis nodosa, epidemiology, Alaskan Eskimos, 97
chronic
acute exacerbation, 2′,5′-oligoadenylate synthetase, 715
cytoskeletal organization, monocytes, 720
Hepatitis B virus
alcoholic liver disease, with hepatocellular carcinoma, 514
analysis of transcripts, infected human livers, 180
chronic, α-fetoprotein monitoring, Chinese patients, 110
compact organization of genome, 322
complexities of DNA integration, 514, 515
control with newborn immunizations, HBsAg-positive mothers, HEPATOLOGY *Elsewhere*, 900
delta hepatitis and, in homosexual men, United States, 872
epidemic, acupuncture and, HEPATOLOGY *Elsewhere*, 509
genome, reduced interferon response, 92
pre-S2 region, 328
protection against transmission, dental practitioners, HEPATOLOGY *Elsewhere*, 902
Hepatitis delta virus
experimental systems for study, 635
homosexual men in United States, 872
Hepatitis non-A/non-B, posttransfusion, assessment, donor blood screening, 449
Hepatitis virus, woodchuck, hepatocellular carcinoma, 461
Hepatocarcinogenesis, enzyme profile, bile ductular epithelial cells, resistance phenotype, 477
Hepatocytes
anoxic injury, 219
asialoglycoprotein receptor-mediated binding, polymeric immunoglobulin A, 229
cirrhotic, alterations, functional receptor expression, 6
differential regulation, glutathione *S*-transferase, 235
hepatobiliary transport, nordeoxycholate side chain conjugates, 861
hepatoprotection by iloprost, CCl_4-induced lipid peroxidation, 830
heterogeneity, 154
human growth factor, clinical significance, fulminant hepatic failure, 875
normal, hepatic stimulator substance, 240
periportal and perivenous, amino acid transport, digitonin/collagenase perfusion, 22
plasma membrane, covalently bound metabolites, isaxonine, 675
proliferation, effect, estrogen and tamoxifen, 614
stimulation of DNA synthesis, Kupffer cells, partial hepatectomy, 405
HEPATOLOGY *Elsewhere*
Anthony: primary lymphoma of liver, 165
Conn and Levy: electroencephalographic triphasic waves, 337
Conn: initial hemorrhage from esophageal varices, 905
Deckelbaum: laser-assisted angioplasty, 338
Dunn: cyclosporin A in murine schistosomiasis, 339
Grace: colchicine treatment of cirrhosis, 655
Henderson: post-shunt portal-systemic encephalopathy, 164
Huxtable: embryotoxicity of pyrrolizidine-containing drugs, 510
Kershenobich, Vargas, Garcia-Tsao, Tamayo, Gent, and Rojkind: colchicine treatment of cirrhosis, 656
Knochel: hypophosphatemia and acute liver failure, 504
Koch and Leffert: liver regeneration, 789
Koff: protection against HBV transmission in dental practitioners, 902
Lefkowitch: presinusoidal portal hypertension model, 336
Lennard: metoprolol-induced hepatitis, 163
Maher: fat-storing cells, 903
Marsh: hepatic vascular toxicity of dacarbazine, 790
Mazer: cholesterol nucleation-promoting activity, 507
McMahon: newborn immunization of $HBsAg^+$ mothers, 900
Mezey: animal models for alcoholic liver disease, 904
Mishkin and Mishkin: androgen receptor and hepatocellular carcinoma, 509
Sauerbruch: laser lithotripsy and bile duct stones, 792
Scharschmidt and Lake: impaired sulfoxidation in primary biliary cirrhosis, 654
Schoen: lyme hepatitis, 335
Shabot: *Chlamydia trachomatis* and ascites, 505
Urban, Dindzans, and Van Thiel: hyperparathyroidism and portacaval shunt, 506
Van Thiel and Gavaler: prostatic hypertrophy in elderly, 167
Wright: targeted therapy for hepatic cancer, 657
HEPATOLOGY *Elsewhere* Correspondence, Arya: acupuncture in epidemic HBV hepatitis, 511
Hepatoma
expression, heat shock protein 70 gene family, 740
growth rate, effect, sex steroid hormones, 621
Hepatoma cells, partial purification, hepatic stimulator substance, 240
Hepatotoxicity, amiodarone, 679
HepG2 cells, regulation of cholesterol metabolism, low- and high-density lipoproteins, 547
Hexachlorobenzene, -induced porphyria, mitochondrial oxidative metabolism, lipid peroxidation, 686
Homosexuals, men in the United States, delta hepatitis, 872
Horseradish peroxidase, transcellular access, molecular charge effect, rat bile, 866
6-Hydroxydopamine, localization of tyrosine-containing nerves, mammalian liver, 839
Hyperammonemia, gluconeogenesis from nitrogen precursors, cirrhosis, 343
Hyperparathyroidism, portacaval shunt and, HEPATOLOGY *Elsewhere*, 505
Hyperplasia, nodular regenerative, bone marrow transplantation, 443
Hyperthyroidism
bile acid metabolism, 852
thyroid hormones, hepatic handling, bilirubin, 314
Hypophosphatemia, role in acute liver failure, HEPATOLOGY *Elsewhere*, 504
Hypothyroidism, thyroid hormones, hepatic handling, bilirubin, 314
Hypoxia, centrilobular liver necrosis, ethanol-induced, 302

Iloprost, effect on carbon tetrachloride-induced lipid peroxidation, hepatoprotection, 830
Iminodiacetic acid, nuclear hepatology progress, 139
Immune response
  cytoskeletal organization and functional changes, monocytes, chronic hepatitis B, 720
  drug-induced allergic hepatitis, isaxonine, 785
  HBsAg and HBcAg detection, HBsAg-positive patients, primary hepatocellular carcinoma, 747
Immunization
  dihydrolipoamide acetyltransferase, mitochondrial antibody generation, 411
  newborns of HBsAg-positive mothers, hepatitis B virus control, HEPATOLOGY *Elsewhere*, 900
  protection against HBV transmission, dental practitioners, HEPATOLOGY *Elsewhere*, 902
Immunoglobulin A
  asialoglycoprotein receptor-mediated binding, 229
  liver and, implications, 763
Immunotargeting, liver cancer, 646
Inferior vena cava, role of membranous obstruction, hepatocellular carcinoma, South African Blacks, 121
Interferon
  -associated 2′,5′-oligoadenylate synthetase, acute and chronic viral hepatitis, 105
  defective response, hepatitis B virus genome, 92
  elevated levels of 2′,5′-oligoadenylate synthetase, acute exacerbation, chronic hepatitis B, 715
γ-Interferon, cytoskeletal organization and functional changes, monocytes, chronic hepatitis B, 720
Iron
  overload
    mitochondrial lipid peroxidation, vitamin E deficiency, 398
    mitochondrial oxidative metabolism, porphyria, 686
  regulation of hepatic transferrin receptor, hereditary hemochromatosis, 1
Isaxonine
  covalently bound metabolites, hepatocyte plasma membrane, 675
  drug-induced allergic hepatitis, 785
Ischemia
  cholangiopathy, floxuridine-induced sclerosing cholangitis, 215
  chronically rejected human liver allografts, histometric analysis, 204
Isoproterenol, effect on hepatic microcirculation, cirrhosis, 820

Ketanserin
  long-term hemodynamic effects, portal hypertension, 88
  verapamil or propranolol, additive effect, alcoholic cirrhosis, 83
α-Keto acid dehydrogenase dihydrolipoamide acyltransferase, reactivity of primary biliary cirrhosis sera, fetal liver cDNA clone, 63
Kidney, stable renal allograft recipients, impaired liver function, 606
Kupffer cells
  characteristics of fat-storing cells, interaction with viruses, 352
  fibronectin release, low-dose endotoxin, 562
  partial hepatectomy, DNA synthesis stimulation, hepatocytes, 405

LAK cells, natural killer cells and, defective function, hepatocellular carcinoma, 471
Laminin, procollagen peptide and, detection, alcoholic hepatitis, 693
Laser, -assisted angioplasty, inferior vena caval obstructions, HEPATOLOGY *Elsewhere*, 338
Laser lithotripsy, treatment of common bile buct stones, HEPATOLOGY *Elsewhere*, 792
Ligand, alterations in functional receptor expression, cirrhotic rat hepatocytes, 6
Lipid peroxidation
  carbon tetrachloride-induced, iloprost effect, hepatoprotection, 830
  mitochondrial, vitamin E deficiency, chronic iron overload, 398
  mitochondrial oxidative metabolism and, porphyria, 686
Lipoproteins
  high-density particles, apolipoprotein E deficiency, alcohol-fed rats, 307
  low- and high-density, cholesterol metabolism regulation, HepG2 cells, 547
  low density, colloidal gold complexes, hepatic metabolism, 380
Liver
  allografts, rejection of, histometric analysis, 204
  alteration of tissue spaces, platelet-activating factor, phenylephrine, 278
  biological effects of epidermal growth factor, 126
  cancer
    immunotargeting, 646
    targeted therapy, HEPATOLOGY *Elsewhere*, 657
  cell membrane antibody, method of detection, 210
  disease
    alcoholic: *see* Alcoholic liver disease
    autoantibodies, nuclear envelope components, 911
    chronic, animal models, 500
    chronic, cholecystolithiasis, 538
    chronic, digoxin-like immunoreactive substances, 363
    chronic, postprandial portal hemodynamics, 815
    chronic active, proline-incorporating cells, 37
    hepatic aldehyde dehydrogenase activity, 704
    nonalcoholic, women's sexual behavior, 698
  drug clearance, aging, determinants, 331
  expression, heat shock protein 70 gene family, 740
  failure, hypophosphatemia, HEPATOLOGY *Elsewhere*, 504
  fulminant hepatic failure, clinical significance, hepatocyte growth factor, 875
  function after long hypothermic preservation, protective effect, vasodilators, 824
  handling of bilirubin, thyroid hormones, 314
  HBsAg and HBcAg detection, HBsAg-positive patients, primary hepatocellular carcinoma, 747
  hepatic microcirculation, vasodilators, cirrhosis, 820
  hepatoprotection by iloprost, CCl_4-induced lipid peroxidation, 830
  IgA and, implications, 763
  impaired function, stable renal allograft recipients, 606
  infected, analysis, hepatitis B virus transcripts, 180
  inferior vena caval obstructions, laser-assisted angioplasty, HEPATOLOGY *Elsewhere*, 338
  localization, ammonia-metabolizing enzymes, 367
  mammalian, localization, tyrosine-containing nerves, 839
  metabolism, colloidal gold-low-density lipoprotein complexes, 380
  microcirculation, fluorescein isothiocyanate-dextran transport, 75
  necrosis, centrilobular hypoxia, ethanol-induced, 302
  parenchymal and Kupffer cells, low-dose endotoxin, fibronectin release, 562
  premalignant, ethionine-induced, chylomicron remnants, 731
  regeneration, DNA synthesis stimulation, Kupffer cells, 405
  vascular toxicity of dacarbazine, HEPATOLOGY *Elsewhere*, 790
  volume and apparent blood flow, effect of aging, healthy persons, 297
  volume change, alcoholic liver fibrosis, 589
Lyme disease, relapsing or reinfectious hepatitis, HEPATOLOGY *Elsewhere*, 335
Lymphoma, primary, HEPATOLOGY *Elsewhere*, 164
Lysosomes, colloidal gold-low-density lipoprotein complexes, hepatic metabolism, 380

Menhaden oil, modulation of ferrochelatase activity, mitochondrial phospholipid fatty acyl groups, 557
Metoprolol, -induced hepatitis, rate of oxidation, HEPATOLOGY *Elsewhere*, 163

Microcirculation, fluorescein isothiocyanate-dextran transport, quantitative study, rat liver, 75
Mitochondria
antibody generation, immunization, dihydrolipoamide acetyltransferase, 411
antimitochondrial autoantibodies, 63
lipid peroxidation, vitamin E deficiency, chronic iron overload, 398
oxidative metabolism, lipid peroxidation, porphyria, 686
phospholipid fatty acyl groups, ferrochelatase activity, dietary manipulation, 557
Monoclonal antibodies
α-fetoprotein, radioimmunodetection, hepatocellular carcinoma, 116
immunolocalization of tumor-associated antigens, hepatocellular carcinoma, 625
immunotargeting in liver cancer, 646
Monocytes
cytoskeletal organization, functional changes, chronic hepatitis B, 720
tumor necrosis factor production, alcoholic hepatitis, 349
Mononuclear cells, elevated levels of 2′,5′-oligoadenylate synthetase, acute exacerbation, chronic hepatitis B, 715
Mucosa, liver and IgA, implications, 763
Myofibroblasts, fat-storing cells and, HEPATOLOGY *Elsewhere*, 903

Natural killer cells, LAK cells and, defective function, hepatocellular carcinoma, 471
Necrosis, ethanol-induced centrilobular hypoxia, 302
Nephrotoxicity, gentamicin, extrahepatic cholestasis, dietary calcium, 519
Nerves, tyrosine-containing, localization, mammalian liver, 839
Neurotransmission, amino acid-ergic, hepatic encephalopathy, thioacetamide liver failure, 594
Nifedipine, effect on hepatic microcirculation, cirrhosis, 820
Nitrogen, precursors, hyperammonemia, cirrhosis, 343
Nitroglycerin
clinical trial of injection sclerotherapy, variceal bleeding, 274
effect on hepatic microcirculation, cirrhosis, 820
Nitroprusside, effect on hepatic microcirculation, cirrhosis, 820
Nordeoxycholate, side chain conjugates, hepatobiliary transport, canalicular transport defect, 861
Notices, 172, 346, 516, 666, 799, 913
Nuclear envelope, components of, autoantibodies, liver diseases, 911

2′,5′-Oligoadenylate synthetase
elevated levels, acute exacerbation, chronic hepatitis B, 715
interferon-associated, acute and chronic viral hepatitis, 105
Oxidation, rate of, metoprolol-induced hepatitis, HEPATOLOGY *Elsewhere*, 163
Oxygen
ethanol-induced centrilobular hypoxia, necrosis, 302
transport and uptake, vasoactive drug effects, cirrhosis, 427

Papaverine
effect on hepatic microcirculation, cirrhosis, 820
liver function, long hypothermic preservation, 824
Parenchyma, fibronectin release, low-dose endotoxin, 562
Pentoxifylline
effect on hepatic microcirculation, cirrhosis, 820
liver function, long hypothermic preservation, 824
Perfluorocarboxylic acids, biochemical effects and zonal heterogeneity, peroxisome proliferation, 570
Perfusion
digitonin/collagenase, amino acid transport, periportal and perivenous hepatocytes, 22
normal and retrograde flow, multiple-indicator dilution technique, 285
Peritonitis, spontaneous bacterial, antibiotic therapy, polymorphonuclear cell count, 423
Permeabilization, selective, monohydroxylated bile acid, endoplasmic reticulum, 663, 665
Peroxisome, proliferation, perfluorocarboxylic acids, 570
Phenobarbital, alterations in functional receptor expression, cirrhotic rat hepatocytes, 6
Phenylephrine, platelet-activating factor and, alteration, hepatic tissue spaces, 278
Phenylhydrazine, -treated adult mice, hemopoietic cell location, liver acinus, 29
Plasma membrane
anoxic hepatocyte injury, 219
hepatocyte, covalently bound metabolites, isaxonine, 675
Platelet-activating factor, phenylephrine and, alteration, hepatic tissue spaces, 278
Polyarteritis nodosa, hepatitis B-associated, epidemiology, Alaskan Eskimos, 97
Polymorphonuclear cells, count, antibiotic therapy, bacterial peritonitis, 423
Popper, Hans, in Memoriam, 669
Porphyria
acute inducible, pharmacokinetics, tin-mesoporphyrin, 882
hexachlorobenzene-induced, mitochondrial oxidative metabolism, lipid peroxidation, 686
Portal hypertension
hemodynamic effects of blood volume restitution, cirrhosis, 808
ketanserin/verapamil/propranolol, additive effect, alcoholic cirrhosis, 83
long-term hemodynamic effects, ketanserin, 88
presinusoidal, model of, HEPATOLOGY *Elsewhere*, 335
promotion of ascites formation, vasodilatation, 797, 798
serotonin blockade, cirrhotic dogs, 265
vasodilator therapy, 896
Portal pressure, systemic hemodynamic changes and, propranolol, portal hypertensive rats, 269
Portal vein, postprandial portal hemodynamics, chronic liver disease, normal patients, 815
Prazosin, effect on hepatic microcirculation, cirrhosis, 820
Pre-S2 antigen
hepatitis B virus, 328
serum titers, acute and chronic type B hepatitis, 175
Primary biliary cirrhosis
autoantibodies, nuclear envelope components, 911
immunization with dihydrolipoamide acetyltransferase, mitochondrial antibody generation, 411
impaired sulfoxidation, HEPATOLOGY *Elsewhere*, 654
mitochondrial autoantigens, 63
vitamin E deficiency, 525
Primary sclerosing cholangitis
floxuridine-induced, ischemic cholangiopathy, 215
immune mechanisms leading to autoimmunity, autoimmune chronic active hepatitis, childhood, 198
Procollagen peptide, serum type III, alcoholic hepatitis detection, 693
Progesterone, effect on hepatoma growth rate, 621
Proline, -incorporating cells, chronic active liver disease, 37
Propranolol
cerebral blood flow, cirrhosis, 439
discrepancy between portal pressure, systemic hemodynamic changes, portal hypertensive rats, 269
effect on hepatic microcirculation, cirrhosis, 820
ketanserin and verapamil, additive effect, alcoholic cirrhosis, 83
Prostate, hypertrophy, elderly cirrhotic patient, HEPATOLOGY *Elsewhere*, 167
Protooncogenes, poly(A⁺)RNA levels, progressive development, hepatocellular carcinoma, 756
Protoporphyria, modulation of ferrochelatase activity, dietary manipulation, mitochondrial phospholipid fatty acyl groups, 557

Pyridoxine, vitamin B_6 repletion, amino acid metabolism, cirrhosis, 582
Pyrrolizidine, -containing drugs, embryotoxicity, HEPATOLOGY *Elsewhere*, 509

Radiation, progress in nuclear hepatology, 139
Receptors
  alterations in functional expression, cirrhotic rat hepatocytes, 6
  androgen, hepatocellular carcinoma, HEPATOLOGY *Elsewhere*, 509
  asialoglycoprotein, IgA binding, 229
  transferrin, regulation of, hereditary hemochromatosis, 1
Regeneration
  hepatic, effect, estrogen and tamoxifen, 614
  human hepatocyte growth factor, clinical significance, fulminant hepatic failure, 875
  transplanted human livers, HEPATOLOGY *Elsewhere*, 789
Renin-aldosterone, atrial natriuretic factor and, volume regulation, cirrhosis, 417
Resection, curative, recurrence, hepatocellular carcinoma, 457
RNA
  analysis of hepatitis B virus transcripts, infected human livers, 180
  poly(A^+)RNA levels, progressive development, hepatocellular carcinoma, 756
RNA, messenger
  differential regulation, glutathione *S*-transferase, hepatocytes, 235
  expression, heat shock protein 70 gene family, 740

Safflower oil, modulation of ferrochelatase activity, mitochondrial phospholipid fatty acyl groups, 557
Schistosoma mansoni, connective tissue matrix constituents, dynamics during infection, 50
Schistosomiasis, murine, cyclosporin suppressive effects, HEPATOLOGY *Elsewhere*, 339
Scintigraphy, progress in nuclear hepatology, 139
Sclerotherapy, injection, controlled clinical trial, variceal bleeding, 274
Serotonin
  blockade in cirrhotic dogs, portal hypertension, 265
  blockers, vasodilator therapy, portal hypertension, 896
Sex steroid hormones, effect on hepatoma growth rate, 621
Sexual behavior, women, nonalcoholic liver disease, 698
Shunt
  embolization of, portal-systemic encephalopathy, HEPATOLOGY *Elsewhere*, 164
  hemodynamic effects of blood volume restitution, portal hypertension, cirrhosis, 808
  portacaval, hyperparathyroidism, HEPATOLOGY *Elsewhere*, 505
Sindbis virus, interaction with fat-storing cells, 352
Sodium, effect of estrogen and tamoxifen, hepatocyte proliferation, 614
Spleen, volume change, alcoholic liver fibrosis, 589
Stimulator substance, hepatic, partial purification, hepatoma cells, 240
Sulfoxidation, impaired, primary biliary cirrhosis, HEPATOLOGY *Elsewhere*, 654

Tamarins, studies of GB hepatitis agent, 186
Tamoxifen, effect on hepatocyte proliferation, 614
T cells, reactivity of primary biliary cirrhosis sera, mitochondrial autoantigen, 63
Technetium-99m, -iminodiacetic acid organic anions, nuclear hepatology progress, 139
Thioacetamide, liver failure, hepatic encephalopathy, 594
Thyroid
  hormones, hepatic handling, bilirubin, 314
  hyperthyroidism, bile acid metabolism, 852
Tin-mesoporphyrin, pharmacokinetics, heme pathway precursors, acute inducible porphyria, 882
Transferrin, receptor, regulation of, hereditary hemochromatosis, 1
Transglutaminase, cross-linking, HBsAg binding, serum albumin, 726
Transplantation
  bone marrow, nodular regenerative hyperplasia, 443
  floxuridine-induced sclerosing cholangitis, ischemic cholangiopathy, 215
  liver
    aminopyrine breath test, outcome, 602
    coagulation factors, 710
    regeneration of, HEPATOLOGY *Elsewhere*, 789
Triolein, modulation of ferrochelatase activity, mitochondrial phospholipid fatty acyl groups, 557
Tubulin
  α-chain, covalent binding, acetaldehyde, 57
  covalent binding of acetaldehyde, 161
Tumor-associated antigens, immunolocalization, hepatocellular carcinoma, 625
Tumor necrosis factor
  acute phase response, pathogenesis, alcoholic liver disease, 497
  production by monocytes, alcoholic hepatitis, 349
Tyrosine hydroxylase, -containing nerves, localization, mammalian liver, 839

Ultrasonography
  abdominal symptoms and gallstone disease, 856
  progress in nuclear hepatology, 139
Urea, cycle enzyme activities, carbon tetrachloride cirrhosis, 373
Urine, metabolism of D-glucaro-1,4-lactone, 552

Vaccine, hepatitis B-associated polyarteritis nodosa, epidemiology, Alaskan Eskimos, 97
Varices
  bleeding
    cirrhotics and, analysis of survival, 801
    injection sclerotherapy, 274
    recurrence prevention with β-blockers, alcoholic cirrhosis, 433
  esophageal, initial hemorrhage, HEPATOLOGY *Elsewhere*, 905
Vasoactive drugs, oxygen transport and uptake, cirrhosis, 427
Vasodilatation, promotion of ascites formation, portal hypertension, 797, 798
Vasodilators
  effect on hepatic microcirculation, cirrhosis, 820
  protective effect, liver function, long hypothermic preservation, 824
  therapy of portal hypertension, 896
Vasopressin, clinical trial of injection sclerotherapy, variceal bleeding, 274
Verapamil
  effect on hepatic microcirculation, cirrhosis, 820
  ketanserin and propranolol, additive effect, alcoholic cirrhosis, 83
Vesicles, cholesterol crystals and, human gallbladder bile, 541
Vimentin
  cytoskeletal organization and functional changes, monocytes, chronic hepatitis B, 720
  fat-storing cells and myofibroblasts, HEPATOLOGY *Elsewhere*, 903
Viruses, interaction with fat-storing cells, 352
Vitamin B_6, repletion in cirrhosis, pyridoxine, amino acid metabolism, 582
Vitamin D, bone disease, chronic childhood cholestasis, 258
Vitamin E
  coming of age, 649
  deficiency
    chronic iron overload, mitochondrial lipid peroxidation, 398
    primary biliary cirrhosis, 525
Volume, regulation in cirrhosis, atrial natriuretic factor, renin-aldosterone, 417

0270-9139/89/0906-0921$02.00/0
HEPATOLOGY
Copyright © 1989 by The American Association for the Study of Liver Diseases
Vol. 9, No. 6, pp. 921-929, 1989
Printed in U.S.A.

Author Index to Volume 9

Abramovitz, M., Ishigaki, S. and Listowsky, I. Differential regulation of glutathione S-transferases in cultured hepatocytes, 235
Abu-Alfa, A., *see* Vakil, 519
Aceves, G., *see* Vorobioff, 88
Ahmed, A., *see* Surh, 63
Akriviadis, E. A., *see* Fong, 423
Alter, M. J., *see* Weisfuse, 872
Altman, N. L., *see* Weisfuse, 872
Ambrosino, G., *see* Francavilla, 614
Amouyal, G., *see* Loeper, 675
André, C., *see* Lassoued, 911
Annoni, G., Colombo, M., Cantaluppi, M. C., Khlat, B., Lampertico, P. and Rojkind, M. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers, 693
Ansari, A., *see* Krams, 411
Anthony, P. P. HEPATOLOGY *Elsewhere*—Primary lymphoma of the liver: A more optimistic point of view, 165
Anwer, M. S., Engelking, L. R. and Lester, R. Correspondence: Reply, 665
Arai, K., *see* Shindo, 715
Arai, M., Nakano, S., Okuno, F., Hirano, Y., Sujita, K., Kobayashi, T., Ishii, H. and Tsuchiya, M. Endotoxin-induced hypercoagulability: A possible aggravating factor of alcoholic liver disease, 846
Arderiu, M., *see* Kravetz, 808
Arendt, R. M., *see* Gerbes, 417
Arya, S. C. HEPATOLOGY *Elsewhere* Correspondence: To the Editor: Acupuncture in epidemic HBV hepatitis: Other ritual surgical procedures in Africa as well, 511
Autuori, F., *see* Hassan, 37
Awad, S. A., *see* Lewis, 710
Ayala, R., *see* Barberá-Guillem, 29

Bach, N., Schaffner, F. and Kapelman, B. Sexual behavior in women with nonalcoholic liver disease, 698
Bacon, B. R., Britton, R. S. and O'Neill, R. Effects of vitamin E deficiency on hepatic mitochondrial lipid peroxidation and oxidative metabolism in rats with chronic dietary iron overload, 398
Bacon, B. R., *see* Feldman, 686
Baldwin, B., *see* Korba, 461
Balistreri, W. F., *see* Muñoz, 525
Balistreri, W. F. Book Review, 909
Ballet, F., *see* Chazouillères, 824
Ballet, F., *see* Marteau, 820
Barbara, L., *see* Gaiani, 815
Barberá-Guillem, E., Ayala, R. and Vidal-Vanaclocha, F. Differential location of hemopoietic colonies within liver acini of postnatal and phenylhydrazine-treated adult mice, 29
Bargagli, A. M., *see* Hassan, 37
Barker, M. E., *see* Bass, 12
Barnard, G. F., Erickson, S. K., Nagata, Y. and Cooper, A. D. Reduced binding and removal of chylomicron remnants by ethionine-induced premalignant liver, 731
Barone, M., *see* Francavilla, 614
Bass, N. M., Barker, M. E., Manning, J. A., Jones, A. L. and Ockner, R. K. Acinar heterogeneity of fatty acid binding protein expression in the livers of male, female and clofibrate-treated rats, 12
Belle, S., *see* Oguma, 204
Bellotto,, D., *see* Berger, 219
Berenguer, J., *see* Hoyos, 449
Berger, M. L., Reynolds, R. C., Hagler, H. K., Bellotto, D., Parsons, D., Mulligan, K. J. and Buja, L. M. Anoxic hepatocyte injury: Role of reversible changes in elemental content and distribution, 219
Bernardi, M., *see* Trevisani, 343
Bernelli-Zazzera, A., *see* Cairo, 740
Berthon, B., *see* Combettes, 663
Beyers, M., *see* Springolo, 116
Bijleveld, C. M. A., Vonk, R. J., Kuipers, F., Havinga, R. and Fernandes, J. Benign recurrent intrahepatic cholestasis: A long-term follow-up study of two patients, 532
Black, D. D., *see* Whitington, 393
Blei, A. T. Editorial—Vasodilator therapy of portal hypertension: Focus on the liver, 896
Bloomer, J., *see* Snover, 443
Bloomer, J. R., *see* Kools, 557
Bollinger, R. R., *see* Yamaguchi, 69
Bolondi, L., *see* Gaiani, 815
Bomford, A., *see* Lombard, 1
Bontempo, F. A., *see* Lewis, 710
Borche, L. *see* Lozano, 911
Bosch, J., *see* Kravetz, 808
Boyer, T. D. Special Article—The glutathione S-transferases: An update, 486
Bréchot, C. Correspondence: To the Editor—Hepatitis B virus in alcoholic liver disease with hepatocellular carcinoma, 514
Bretagne, J.-F., *see* Leray, 249
Brissot, P., *see* Leray, 249
Britton, R. S., *see* Bacon, 398
Brown, W. R. and Kloppel, T. M. Special Article—The liver and IgA: Immunological, cell biological and clinical implications, 763
Buja, L. M., *see* Berger, 219
Bukofzer, S., *see* Kew, 121
Burger, H.-J., Gebhardt, R., Mayer, C. and Mecke, D. Different capacities for amino acid transport in periportal and perivenous hepatocytes isolated by digitonin/collagenase perfusion, 22
Burroughs, A. K., Mezzanotte, G., Phillips, A., McCormick, P. A. and McIntyre, N. Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates, 801
Bursch, W., Taper, H. S., Somer, M. P., Meyer, S., Putz, B. and Schulte-Hermann, R. Histochemical and biochemical studies on the effect of the prostacyclin derivative Iloprost on CCl_4-induced lipid peroxidation in rat liver and its significance for hepatoprotection, 830
Burt, A. D., Tiniakos, D., MacSween, R. N. M., Griffiths, M. R., Wisse, E. and Polak, J. M. Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liver, 839
Burwen, S. J., *see* Marti, 126

Cairo, G., Schiaffonati, L., Rappocciolo, E., Tacchini, L. and Bernelli-Zazzera, A. Expression of different members of heat shock protein 70 gene family in liver and hepatomas, 740
Calès, P., Pierre-Nicolas, M., Guell, A., Mauroux, J.-L., Franco-Sempe, A., Vinel, J.-P., Geraud, G. and Pascal, J.-P. Propranolol does

not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy, 439
Campion, J.-P., *see* Leray, 249
Cantaluppi, M. C., *see* Annoni, 693
Carithers, R. L., Jr. Book Review, 342
Caruso, A., *see* Lewis, 679
Castilla, A., *see* Prieto, 720
Cerini, R., *see* Hadengue, 83
Cerini, R., *see* Koshy, 269
Charles, R., *see* Moorman, 367
Chazouillères, O., Ballet, F., Chrétien, Y., Marteau, P., Rey, C., Maillard, D. and Poupon, R. Protective effect of vasodilators on liver function after long hypothermic preservation: A study in the isolated perfused rat liver, 824
Chazouillères, O., *see* Marteau, 820
Chen, D-S., *see* Hsu, 747
Chen, W., Gendrault, J.-L., Steffan, A.-M., Jeandidier, E. and Kirn, A. Isolation, culture and main characteristics of mouse fat-storing cells: Interaction with viruses, 352
Chiou, T-J., *see* Hsu, 747
Cho, E., *see* Vincent, 562
Chrétien, Y., *see* Chazouillères, 824
Chrétien, Y., *see* Marteau, 820
Chu, C.-M., Liaw, Y.-F., Pao, C. C. and Huang, M.-J. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers, 452
Chung, C. T., *see* Miller, 322
Cilento, E. V., *see* Stock, 75
Civeira, M-P., *see* Prieto, 720
Claret, M., *see* Combettes, 663
Clement, D., *see* McMahon, 97
Coetzee, M., *see* Francavilla, 614
Cohen, D. A., *see* McClain, 349
Cohen, J. I. Special Article—Hepatitis A virus: Insights from molecular biology, 889
Coll, P., *see* Sainz, 662
Colman, J. Book Review, 513
Colombo, M., de Franchis, R., Tommasini, M., Sangiovanni, A. and Dioguardi, N. β-Blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial, 433
Colombo, M., *see* Annoni, 693
Combettes, L., Berthon, B. and Claret, M. Correspondence: To the Editor—Selective permeabilization of the endoplasmic reticulum by monohydroxylated bile acids in liver, 663
Conn, H. O. and Levy, L. L. HEPATOLOGY *Elsewhere*—The nonspecificity of electroencephalographic triphasic waves: The emperor defrocked, 337
Conn, H. O. HEPATOLOGY *Elsewhere*—The initial hemorrhage from esophageal varices, 908
Conradie, J. D., *see* Springolo, 116
Cooper, A. D., *see* Barnard, 731
Cope, L. H., *see* Wynne, 297
Coppel, R. L., *see* Krams, 411
Coppel, R. L., *see* Surh, 63
Cote, P. J., *see* Korba, 461
Courvalin, J. C., *see* Lassoued, 911
Crowe, J., *see* Lombard, 1
Czaja, A. J., *see* Hay, 193

Daikuhara, Y., *see* Tsubouchi, 875
D'Amico, P., *see* Mathis, 477
Daniels, C. K., Schmucker, D. L. and Jones, A. L. Hepatic asialoglycoprotein receptor-mediated binding of human polymeric immunoglobulin A, 229
Danner, D. J., *see* Surh, 63
Danon, F., *see* Lassoued, 911
d'Arville, C. N., Le, M., Kloppel, T. M. and Simon, F. R. Alterations in the functional expression of receptors on cirrhotic rat hepatocytes, 6
Deckelbaum, L. I. HEPATOLOGY *Elsewhere*—Laser-assisted angioplasty of inferior vena caval obstructions: What's good for the artery is good for the vein, 338
DeFaria, E., *see* Yamaguchi, 69
de Franchis, R., *see* Colombo, 433
De Groote, J., *see* Van Steenbergen, 314
de Haan, J., *see* Oude Elferink, 861
Demetris, A. J., *see* Oguma, 204
Descatoire, V., *see* Loeper, 675
Deugnier, Y., *see* Leray, 249
De Vos, R., *see* Van Steenbergen, 314
Dhumeaux, D., *see* Lassoued, 911
Dice, J. F. Book Review, 908
Dickson, E. R., *see* Surh, 63
DiLeo, A., *see* Francavilla, 614
Dindzans, V. J., *see* Urban, 506
Dioguardi, N., *see* Colombo, 433
Dunn, M. A. HEPATOLOGY *Elsewhere*—Suppressive effects of cyclosporin A in murine schistosomiasis, 339

Eagon, P., *see* Francavilla, 614
Ebara, M., *see* Kondo, 751
Ebner, J., *see* Zimmermann, 594
El Meneza, S., Olds, G. R., Kresina, T. F. and Mahmoud, A. A. F. Dynamics of hepatic connective tissue matrix constituents during murine *Schistosoma mansoni* infection, 50
Endo, K., *see* Takahashi, 625
Endo, Y., *see* Kurai, 175
Engelking, L. R., *see* Anwer, 665
Enticott, M., *see* Karayiannis, 186
Epstein, O. Book Review, 512
Erdstein, J., *see* Mishkin, 509
Erdstein, J., Wisebord, S., Mishkin, S. Y. and Mishkin, S. The effect of several sex steroid hormones on the growth rate of three Morris hepatoma tumor lines, 621
Erickson, S. K., *see* Barnard, 731
Ertan, A. Book Review, 909
Esser, J., *see* Springolo, 116
Esser, J. D., *see* Kew, 121

Fasy, T. M., *see* Thung, 726
Feldman, E. S. and Bacon, B. R. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload, 686
Ferenci, P., *see* Zimmermann, 594
Fernandes, J., *see* Bijleveld, 532
Fevery, J., *see* Van Steenbergen, 314
Fields, H. A., *see* Weisfuse, 872
Fischer, J. E. Book Review, 660
Fleig, W. E. and Hoss, G. Partial purification of rat hepatic stimulator substance and characterization of its action on hepatoma cells and normal hepatocytes, 240
Fong, T.-L., Akriviadis, E. A., Runyon, B. A. and Reynolds, T. B. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis, 423
Francavilla, A., Polimeno, L., DiLeo, A., Barone, M., Ove, P., Coetzee, M., Eagon, P., Makowka, L., Ambrosino, G., Mazzaferro, V. and Starzl, T. E. The effect of estrogen and tamoxifen on hepatocyte proliferation *in vivo* and *in vitro*, 614
Franco, D., *see* Kemeny, 253
Franco-Sempe, A., *see* Calès, 439
Frey, B. M., *see* Frey, 606
Frey, F. J., Schaad, H. J., Renner, E. L., Horber, F. F., Frey, B. M. and

Preisig, R. Impaired liver function in stable renal allograft recipients, 606
Fry, M., *see* Karayiannis, 186
Fujiwara, T., *see* Tarao, 589

Gaiani, S., Bolondi, L., Li Bassi, S., Santi, V., Zironi, G. and Barbara, L. Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease, 815
Galbraith, R. A. and Kappas, A. Pharmacokinetics of tin-mesoporphyrin in man and the effects of tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria, 882
Gallart, T., *see* Lozano, 911
Garcia-Tsao, G., *see* Kershenobich, 656
Garcia-Tsao, G., *see* Vorobioff, 88
Garrigues, V., *see* Hoyos, 449
Gasbarrini, G., *see* Trevisani, 343
Gavaler, J. S., *see* Van Thiel, 167
Gebhardt, R., *see* Burger, 22
Gendrault, J.-L., *see* Chen, 352
Gengo, T. F., *see* Mathis, 477
Gent, M., *see* Kershenobich, 656
Geraud, G., *see* Calès, 439
Gerber, M. A., *see* Thung, 726
Gerber, M. A. and Thung, S. N. Editorial—The pre-S2 region of hepatitis B virus: More questions than answers, 328
Gerbes, A. L., Wernze, H., Arendt, R. M., Riedel, A., Sauerbruch, T. and Paumgartner, G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis, 417
Gerin, J. L., *see* Korba, 461
Gershwin, M. E., *see* Krams, 411
Gershwin, M. E., *see* Surh, 63
Gimson, A. E. S., *see* Westaby, 274
Girod, C., *see* Koshy, 269
Girones, R., *see* Miller, 322
Gohda, E., *see* Tsubouchi, 875
Goldberg, B. B. Book Review, 341
Goresky, C. A., *see* St-Pierre, 285
Gorgas, K., *see* Just, 570
Govindarajan, S. Book Review, 660
Grace, N. D. HEPATOLOGY *Elsewhere*—Colchicine treatment of cirrhosis: Questions, 655
Griffiths, M. R., *see* Burt, 839
Groszmann, R., *see* Vorobioff, 88
Guarner, C., *see* Sainz, 662
Guell, A., *see* Calès, 439
Gumucio, J. J. Editorial—Hepatocyte heterogeneity: The coming of age. From the description of a biological curiosity to a partial understanding of its physiological meaning and regulation, 154

Hadengue, A., Moreau, R., Cerini, R., Koshy, A. Lee, S. S. and Lebrec, D. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: Search for an additive effect, 83
Hadengue, A., *see* Koshy, 269
Hadengue, A., *see* Moreau, 427
Hadler, S. C., *see* Weisfuse, 872
Hagey, L. R., *see* Oude Elferink, 861
Hagler, H. K., *see* Berger, 219
Hamilton, R. L., *see* Renaud, 380
Han, S.-H., *see* Su, 180
Hardison, W. G. M., Lowe, P. J. and Shanahan, M. Effect of molecular charge on para- and transcellular access of horseradish peroxidase into rat bile, 866
Harrison, T. J. Correspondence: Reply, 515
Hartl, F-U., *see* Just, 570
Hashimoto, S., *see* Tsubouchi, 875
Hassan, G., Stefanini, S., Bargagli, A. M. and Autuori, F. Proline-incorporating cells in chronic active liver diseases, 37
Havel, R. J., *see* Renaud, 380
Havinga, R., *see* Bijleveld, 532
Hay, J. E., Czaja, A. J., Rakela, J. and Ludwig, J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients, 193
Hayashi, K., *see* Tarao, 589
Hayes, P. C., *see* Westaby, 274
Heathcote, J., Kim, Y.-I., Yim, C. K., LeBrocq, J. and Read, S. E. Interferon-associated lymphocyte 2′, 5′-oligoadenylatesynthetase in acute and chronic viral hepatitis, 105
Heilman, C. A., *see* Huber, 756
Heinemann, P., *see* Just, 570
Heirwegh, K. P. M., *see* Van Steenbergen, 314
Henderson, J. M., Scott, S. S., Merrill, A. H., Hollins, B. and Kutner, M. H. Vitamin B_6 repletion in cirrhosis with oral pyridoxine: Failure to improve amino acid metabolism, 582
Henderson, J. M. HEPATOLOGY *Elsewhere*—Treatment of post-shunt portal-systemic encephalopathy by embolization of the shunt, 164
Hernandez-Ortiz, J., *see* Vorobioff, 88
Heubi, J. E., Hollis, B. W., Specker, B. and Tsang, R. C. Bone disease in chronic childhood cholestasis. I. Vitamin D absorption and metabolism, 258
Heubi, J. E., *see* Muñoz, 525
Heyward, W. L., *see* McMahon, 97
Hickman, R., *see* Oakland, 602
Hill, H. D., *see* Kools, 557
Hirano, Y., *see* Arai, 846
Hirono, S., *see* Tsubouchi, 875
Hirooka, N., *see* Kondo, 751
Ho, K-J., *see* MacFadyen, 552
Hodkinson, J., *see* Kew, 121
Hofmann, A. F., *see* Oude Elferink, 861
Hollins, B., *see* Henderson, 582
Hollis, B. W., *see* Heubi, 258
Holman, R. T., *see* Kools, 557
Hood, A., *see* Thung, 726
Horber, F. F., *see* Frey, 606
Hörtnagl, H., *see* Zimmermann, 594
Hoshino, H., *see* Tarao, 589
Hoss, G., *see* Fleig, 240
Hoyos, M., Sarrión, J. V., Pérez-Castellanos, T., Prieto, M., Marty, M. L., Garrigues, V. and Berenguer, J. Prospective assessment of donor blood screening for antibody to hepatitis B core antigen as a means of preventing posttransfusion non-A, non-B, hepatitis, 449
Hsu, H-C., Wu, T-T., Sheu, J-C., Wu, C-Y., Chiou, T-J., Lee, C-S. and Chen, D-S. Biologic significance of the detection of HBsAg and HBcAg in liver and tumor from 204 HBsAg-positive patients with primary hepatocellular carcinoma, 747
Huang, M.-J., *see* Chu, 452
Huber, B. E., Heilman, C. A. and Thorgeirsson, S. S. Poly(A^+) RNA levels of growth-, differentiation- and transformation-associated genes in the progressive development of hepatocellular carcinoma in the rat, 756
Huet, P.-M., *see* Mastaï, 265
Huxtable, R. J. HEPATOLOGY *Elsewhere*—Human embryotoxicity of pyrrolizidine-containing drugs, 510
Hynes, M., *see* Lombard, 1

Iimori, K., *see* Tarao, 589
Iino, S., *see* Kurai, 175
Ikeda, T., *see* Tarao, 589
Ishak, K. G., *see* Lewis, 679
Ishigaki, S., *see* Abramovitz, 235

Ishii, H., *see* Arai, 846
Israel, Y. Editorial—Covalent binding of acetaldehyde to liver tubulin: A step in the right direction, 161
Ito, Y., *see* Tarao, 589

Jackson, L. K., *see* Lewis, 679
James, O. F. W., *see* Wynne, 297
Jansen, P. L. M., *see* Oude Elferink, 861
Javitt, N. B. Book Review, 794
Jeandidier, E., *see* Chen, 352
Jennett, R. B., Sorrell, M. F., Saffari-Fard, A., Ockner, J. L. and Tuma, D. J. Preferential covalent binding of acetaldehyde to the α-chain of purified rat liver tubulin, 57
Jones, A. L., *see* Bass, 12
Jones, A. L., *see* Daniels, 229
Jones, A. L., *see* Marti, 126
Jørgensen, T. Abdominal symptoms and gallstone disease: An epidemiological investigation, 856
Jouanolle, A.-M., *see* Leray, 249
Judson, F. N., *see* Weisfuse, 872
Jüngst, D., *see* Schriever, 541
Just, W. W., Gorgas, K., Hartl, F-U., Heinemann, P., Salzer, M. and Schimassek, H. Biochemical effects and zonal heterogeneity of peroxisome proliferation induced by perfluorocarboxylic acids in rat liver, 570

Kabadi, V. M. Correspondence: Reply, 344
Kalser, S. C. Correspondence: To the Editor—Don't give up on your grant application, 796
Kaneko, S., *see* Miller, 322
Kanematsu, T., *see* Matsumata, 457
Kang, Y. G., *see* Lewis, 710
Kapadia, C. R. Book Review, 170
Kapelman, B., *see* Bach, 698
Kappas, A., *see* Galbraith, 882
Karayiannis, P., Petrovic, L. M., Fry, M. Moore, D., Enticott, M., McGarvey, M. J., Scheuer, P. J. and Thomas, H. C. Studies of GB hepatitis agent in tamarins, 186
Katsumoto, F., Miyazaki, K. and Nakayama, F. Stimulation of DNA synthesis in hepatocytes by Kupffer cells after partial hepatectomy, 405
Keegan-Rogers, V. and Wu, G. Y. Editorial—Immunotargeting in the diagnosis and treatment of liver cancer, 646
Kehrer, B. H., *see* Whitington, 393
Kemeny, F., Vadrot, J., Wu, A., Smadja, C., Meakins, J. L. and Franco, D. Morphological and histological features of resected hepatocellular carcinoma in cirrhotic patients in the West, 253
Kershenobich, D., Vargas, F., Garcia-Tsao, G., Tamayo, R. P., Gent, M. and Rojkind, M. HEPATOLOGY *Elsewhere*—Colchicine treatment of cirrhosis: Answers, 656
Kew, M. C., McKnight, A., Hodkinson, J., Bukofzer, S. and Esser, J. D. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern Africa Blacks, 121
Kew, M. C., *see* Springolo, 116
Keyser, A. J., *see* Yang, 363
Khlat, B., *see* Annoni, 693
Kim, C. H., *see* Ludwig, 215
Kim, Y.-I., *see* Heathcote, 105
Kirn, A., *see* Chen, 352
Kiss, J. E., *see* Lewis, 710
Kloppel, T. M., *see* Brown, 763
Kloppel, T. M., *see* d'Arville, 6
Knochel, J. P. HEPATOLOGY *Elsewhere*—Does hypophosphatemia play a role in acute liver failure?, 504
Kobayashi, T., *see* Arai, 846
Koch, K. S. and Leffert, H. L. HEPATOLOGY *Elsewhere*—Do transplanted human livers regenerate?, 789
Koff, R. S. HEPATOLOGY *Elsewhere*—Protection against the transmission of hepatitis B virus in dental practitioners: Better gloves, earlier vaccination, or both?, 902
Koike, K., *see* Kurai, 175
Koizumi, M., *see* Takahashi, 625
Kondo, F., Wada, K., Nagato, Y., Nakajima, T., Kondo, Y., Hirooka, N., Ebara, M., Ohto, M. and Okuda, K. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria, 751
Kondo, Y., *see* Kondo, 751
Kools, A. M., Straka, J. G., Hill, H. D., Whitmer, D. I., Holman, R. T. and Bloomer, J. R. Modulation of hepatic ferrochelatase activity by dietary manipulation of mitochondrial phospholipid fatty acyl groups, 557
Korba, B. E., Wells, F. V., Baldwin, B., Cote, P. J., Tennant, B. C., Popper, H. and Gerin, J. L. Hepatocellular carcinoma in woodchuck hepatitis virus- infected woodchucks: Presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections, 461
Korula, J., *see* Yang, 363
Koshy, A., Girod, C., Lee, S. S., Hadengue, A., Cerini, R. and Lebrec, D. Discrepancy between portal pressure and systemic hemodynamic changes after incremental doses of propranolol in awake portal hypertensive rats, 269
Koshy, A., *see* Hadengue, 83
Kottke, B. A., *see* Ranganathan, 547
Krams, S. M., Surh, C. D., Coppel, R. L., Ansari, A., Ruebner, B. and Gershwin, M. E. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis, 411
Kravetz, D., Bosch, J., Arderiu, M., Pizcueta, M. P. and Rodés, J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting, 808
Kresina, T. F., *see* El Meneza, 50
Krishnamurthy, G. T., *see* Krishnamurthy, 139
Krishnamurthy, S. and Krishnamurthy, G. T. Special Article—Technetium-99m-iminodiacetic acid organic anions: Review of biokinetics and clinical application in hepatology, 139
Krom, R. A. F., *see* Ludwig, 215
Kuipers, F., *see* Bijleveld, 532
Kurai, K., Iino, S., Koike, K., Mitamura, K., Endo, Y. and Oka, H. Serum titers of pre-S(2) antigen in patients with acute and chronic type B hepatitis: Relation to serum aminotransferase activity and other hepatitis B virus markers, 175
Kutner, M. H., *see* Henderson, 582

Lai, C.-L., *see* Lok, 110
Lake, J. R., *see* Scharschmidt, 654
Lambert, K. J., *see* Oude Elferink, 861
Lamers, W. H., *see* Moorman, 367
Lampertico, P., *see* Annoni, 693
Landis, B., *see* Yamaguchi, 69
Lanier, A. P., *see* McMahon, 97
Lapointe, D. S. and Olson, M. S. Alteration of hepatic tissue spaces by platelet-activating factor and phenylephrine, 278
Larrey, D., *see* Loeper, 675
Lassmann, H., *see* Zimmermann, 594
Lassoued, K., Danon, F., André, C., Courvalin, J. C. and Dhumeaux, D. Correspondence: To the Editor—Liver diseases associated with autoantibodies directed to nuclear envelope components, 911
Le, M., *see* d'Arville, 6
Lebrec, D., *see* Hadengue, 83

Lebrec, D., *see* Koshy, 269
Lebrec, D., *see* Moreau, 427
LeBrocq, J., *see* Heathcote, 105
Lee, C-S., *see* Hsu, 747
Lee, S.-D., Lo, K.-J., Tsai, Y.-T., Wu, J.-C. and Wu, T.-C. HBsAg carrier infants with serum anti-HBc negativity, 102
Lee, S. S., *see* Hadengue, 83
Lee, S. S., *see* Koshy, 269
Lee, S. S., *see* Moreau, 427
Lee, W.-F., *see* St-Pierre, 285
Leffert, H. L., *see* Koch, 789
Lefkowitch, J. H. HEPATOLOGY *Elsewhere*—A model of presinusoidal portal hypertension, 336
Lehry, D., *see* Leray, 249
Lennard, M. S. HEPATOLOGY *Elsewhere*—Metoprolol-induced hepatitis: Is the rate of oxidation related to drug-induced hepatotoxicity?, 163
Leray, G., Deugnier, L., Jouanolle, A.-M., Lehry, D., Bretagne, J.-F., Campion, J.-P., Brissot, P. and Le Treut, A. Biochemical aspects of α-L-fucosidase in hepatocellular carcinoma, 249
Lester, R., *see* Anwer, 665
Le Treut, A., *see* Leray, 249
Lettéron, P., *see* Loeper, 675
Lever, A. M. L., *see* Onji, 92
Levin, J., *see* Springolo, 116
Levy, L. L., *see* Conn, 337
Lewis, J. H., Bontempo, F. A., Awad, S. A., Kang, Y. G., Kiss, J. E., Ragni, M. V., Spero, J. A. and Starzl, T. E. Liver transplantation: Intraoperative changes in coagulation factors in 100 first transplants, 710
Lewis, J. H., Ranard, R. C., Caruso, A., Jackson, L. K., Mullick, F., Ishak, K. G., Seeff, L. B. and Zimmerman, H. J. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients, 679
Leyten, R., *see* Van Steenbergen, 314
Liaw, Y.-F., *see* Chu, 452
Liaw, Y-F., *see* Sheen, 538
Li Bassi, S., *see* Gaiani, 815
Lin, L.-H., *see* Su, 180
Lin, R. C., Lumeng, L. and Phelps, V. L. Serum high-density lipoprotein particles of alcohol-fed rats are deficient in apolipoprotein E, 307
Listowsky, I., *see* Abramovitz, 235
Lo, K.-J., *see* Lee, 102
Lobo-Yeo, A., McSorley, C., McFarlane, B. M., Mieli-Vergani, G., Mowat, A. P. and Vergani, D. Detection of anti-liver cell membrane antibody using a human hepatocellular carcinoma cell line, 210
Lobo-Yeo, A., *see* Mieli-Vergani, 198
Loeper, J., Descatoire, V., Amouyal, G., Lettéron, P., Larrey, D. and Pessayre, D. Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man, 675
Lok, A. S. F. and Lai, C.-L. α-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma, 110
Lombard, M., Bomford, A., Hynes, M., Naoumov, N. V., Roberts, S., Crowe, J. and Williams, R. Regulation of the hepatic transferrin receptor in hereditary hemochromatosis, 1
Losowsky, M. S., *see* Thornton, 797
Lowe, P. J., *see* Hardison, 866
Lozano, F., Parés, A., Borche, L., Plana, M., Gallart, T., Rodés, J. and Vives, J. Correspondence: Reply, 911
Ludwig, J., Kim, C. H., Wiesner, R. H, and Krom, R. A. F. Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy?, 215
Ludwig, J., *see* Hay, 193
Lui, W.-Y., *see* Su, 180
Lumeng, L., *see* Lin, 307
MacFadyen, A. and Ho, K-J. D-Glucaro-1,4-lactone: Its excretion in the bile and urine and effect on the biliary secretion of β-glucuronidase after oral administration in rats, 552
Mackay, I. R., *see* Surh, 63
MacSween, R. N. M., *see* Burt, 839
Maddrey, W. C., *see* Muñoz, 525
Maher, J. J. HEPATOLOGY *Elsewhere*—Fat-storing cells and myofibroblasts: One cell or two?, 903
Mahmoud, A. A. F., *see* El Meneza, 50
Maillard, D., *see* Chazouillères, 824
Maki, A., *see* Takahashi, 625
Makowka, L., *see* Francavilla, 614
Manning, J. A., *see* Bass, 12
Marsh, J. C. HEPATOLOGY *Elsewhere*—Hepatic vascular toxicity of dacarbazine (DTIC): Not a rare complication, 790
Marteau, P., Ballet, F., Chazouillères, O., Chrétien, Y., Rey, C., Petit, D. and Poupon, R. Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver, 820
Marteau, P., *see* Chazouillères, 824
Marti, U., Burwen, S. J. and Jones, A. L. Special Article—Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: An update, 126
Marty, M. L., *see* Hoyos, 449
Mason, W. S. and Taylor, J. M. Special Article—Experimental systems for the study of hepadnavirus and hepatitis delta virus infections, 635
Mastaï, R., Rocheleau, B. and Huet, P.-M. Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension, 265
Mathis, G. A., Walls, S. A., D'Amico, P., Gengo, T. F. and Sirica, A. E. Enzyme profile of rat bile ductular epithelial cells in reference to the resistance phenotyped in hepatocarcinogenesis, 477
Matsumata, T., Kanematsu, T., Takenaka, K., Yoshida, Y., Nishizaki, T. and Sugimachi, K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma, 457
Matsumoto, M., *see* Shindo, 715
Mauroux, J.-L., *see* Calès, 439
Mayer, C., *see* Burger, 22
Mazer, N. A. HEPATOLOGY *Elsewhere*—Quantification of cholesterol nucleation-promoting activity in human gallbladder bile: A 'homeopathic' approach?, 507
Mazzaferro, V., *see* Francavilla, 614
McClain, C. J. and Cohen, D. A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis, 349
McCormick, P. A., *see* Burroughs, 801
McCullough, A. J., *see* Mullen, 500
McCuskey, R. S., *see* Stock, 75
McFarlane, B. M., *see* Lobo-Yeo, 210
McFarlane, B. M., *see* Mieli-Vergani, 198
McFarlane, I. G., *see* Mieli-Vergani, 198
McGarvey, M. J., *see* Karayiannis, 186
McGlave, P., *see* Snover, 443
McIntyre, N., *see* Burroughs, 801
McKnight, A., *see* Kew, 121
McMahon, B. J., Heyward, W. L., Templin, D. W., Clement, D. and Lanier, A. P. Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: Clinical and epidemiologic features and long-term follow-up, 97
McMahon, B. J. HEPATOLOGY *Elsewhere*—Immunization of newborns of HBsAg-positive mothers: A successful first step in control of hepatitis B virus in Taiwan, 900
McSorley, C., *see* Lobo-Yeo, 210
Meakins, J. L., *see* Kemeny, 253

Mecke, D., *see* Burger, 22
Merrill, A. H., *see* Henderson, 582
Meyer, S., *see* Bursch, 830
Mezey, E. HEPATOLOGY *Elsewhere*—Animal models for alcoholic liver disease, 904
Mezzanotte, G., *see* Burroughs, 801
Mieli-Vergani, G., Lobo-Yeo, A., McFarlane, B. M., McFarlane, I. G., Mowat, A. P. and Vergani, D. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood, 198
Mieli-Vergani, G., *see* Lobo-Yeo, 210
Mieli-Vergani, G., *see* Senaldi, 345
Miller, R. H., Kaneko, S., Chung, C. T., Girones, R. and Purcell, R. H. Special Article—Compact organization of the hepatitis B virus genome, 322
Mishkin, S., Mishkin, S. Y. and Erdstein, J. HEPATOLOGY *Elsewhere*—Androgen receptor analysis on needle biopsy of the liver: A step closer in determining whether hepatocellular carcinomas are sex hormone-sensitive, 509
Mishkin, S., *see* Erdstein, 621
Mishkin, S. Y., *see* Erdstein, 621
Mishkin, S. Y., *see* Mishkin, 509
Mitamura, K., *see* Kurai, 175
Miyazaki, H., *see* Tsubouchi, 875
Miyazaki, K., *see* Katsumoto, 405
Moore, D., *see* Karayiannis, 186
Moorman, A. F. M., Vermeulen, J. L. M., Charles, R. and Lamers, W. H. Localization of ammonia-metabolizing enzymes in human liver: Ontogenesis of heterogeneity, 367
Moreau, R., Lee, S. S., Hadengue, A., Ozier, Y., Sicot, C. and Lebrec, D. Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: Effects of vasoactive drugs, 427
Moreau, R., *see* Hadengue, 83
Morte, S., *see* Prieto, 720
Motohashi, I., *see* Tarao, 589
Mowat, A. P., *see* Lobo-Yeo, 210
Mowat, A. P., *see* Mieli-Vergani, 198
Mowat, A. P., *see* Senaldi, 345
Mujais, S. K., *see* Vakil, 519
Mullen, K. D. and McCullough, A. J. Editorial—Problems with animal models of chronic liver disease: Suggestions for improvement in standardization, 500
Mullick, F., *see* Lewis, 679
Mulligan, K. J., *see* Berger, 219
Muñoz, S. J., Heubi, J. E., Balistreri, W. F. and Maddrey, W. C. Vitamin E deficiency in primary biliary cirrhosis: Gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins, 525
Mutch, E., *see* Wynne, 297
Muto, Y., *see* Tsubouchi, 875

Nagata, Y., *see* Barnard, 731
Nagato, Y., *see* Kondo, 751
Nakajima, T., *see* Kondo, 751
Nakano, S., *see* Arai, 846
Nakayama, F., *see* Katsumoto, 405
Nakayama, H., *see* Tsubouchi, 875
Naoumov, N. V., *see* Lombard, 1
Nishizaki, T., *see* Matsumata, 457
Nord, H. J. Book Review, 171

Oakland, C. D. H., Hickman, R. and Terblanche, J. The aminopyrine breath test predicts the outcome of hepatic transplantation in pigs, 602
Ockner, J. L., *see* Jennett, 57
Ockner, R. K., *see* Bass, 12
Odagiri, K., *see* Tarao, 589
Oguma, S., Belle, S., Starzl, T. E. and Demetris, A. J. A histometric analysis of chronically rejected human liver allografts: Insights into the mechanisms of bile duct loss: Direct immunologic and ischemic factors, 204
Ohto, M., *see* Kondo, 751
Oikawa, Y., *see* Tarao, 589
Oka, H., *see* Kurai, 175
Okuda, K., *see* Kondo, 751
Okuno, F., *see* Arai, 846
Okuno, T., *see* Shindo, 715
Olds, G. R., *see* El Meneza, 50
Olson, M. S., *see* Lapointe, 278
O'Malley, P. M., *see* Weisfuse, 872
O'Neill, R., *see* Bacon, 398
Onishi, S., *see* Saibara, 471
Onji, M., Lever, A. M. L., Saito, I. and Thomas, H. C. Defective response to interferons in cells transfected with the hepatitis B virus genome, 92
Ostrow, D. G., *see* Weisfuse, 872
Oude Elferink, R. P. J., de Haan, J., Lambert, K. J., Hagey, L. R., Hofmann, A. F. and Jansen, P. L. M. Selective hepatobiliary transport of nordeoxycholate side chain conjugates in mutant rats with a canalicular transport defect, 861
Ove, P., *see* Francavilla, 614
Ozawa, K., *see* Takahashi, 625
Ozier, Y., *see* Moreau, 427
Ozturk, M., *see* Takahashi, 625

Pang, K. S., *see* St-Pierre, 285
Pao, C. C., *see* Chu, 452
Parés, A., *see* Lozano, 911
Parsons, D., *see* Berger, 219
Pascal, J.-P., *see* Calès, 439
Pauletzki, J., Stellaard, F. and Paumgartner, G. Bile acid metabolism in human hyperthyroidism, 852
Paumgartner, G., *see* Gerbes, 417
Paumgartner, G., *see* Pauletzki, 852
P'eng, F.-K., *see* Su, 180
Pérez-Castellanos, T., *see* Hoyos, 449
Pessayre, D., *see* Loeper, 675
Petit, D., *see* Marteau, 820
Petrovic, L. M., *see* Karayiannis, 186
Phelps, V. L., *see* Lin, 307
Phillips, A., *see* Burroughs, 801
Phillips, M. J. Book Review, 341
Picabea, E., *see* Vorobioff, 88
Pierre-Nicolas, M., *see* Calès, 439
Pifl, C., *see* Zimmermann, 594
Pizcueta, M. P., *see* Kravetz, 808
Plana, M., *see* Lozano, 911
Pohl, L. R. Editorial—Drug-induced allergic hepatitis: Does isaxonine fall into this category?, 785
Polak, J. M., *see* Burt, 839
Polimeno, L., *see* Francavilla, 614
Polson, R. J., *see* Westaby, 274
Popper, H., *see* Korba, 461
Poupon, R., *see* Chazouillères, 824
Poupon, R., *see* Marteau, 820
Preisig, R., *see* Frey, 606
Prieto, J., Castilla, A., Subirá, M-L., Serrano, M., Morte, S. and Civeira, M-P. Cytoskeletal organization and functional changes in monocytes from patients with chronic hepatitis B: Relationship with viral replication, 720
Prieto, M., *see* Hoyos, 449
Purcell, R. H., *see* Miller, 322
Putz, B., *see* Bursch, 830

Quarfordt, S., *see* Yamaguchi, 69

Ragni, M. V., *see* Lewis, 710
Rakela, J., *see* Hay, 193
Ranard, R. C., *see* Lewis, 679
Ranganathan, S. and Kottke, B. A. Studies on the regulation of cholesterol metabolism by low- and high-density lipoproteins in HepG2 cells, 547
Rappocciolo, E., *see* Cairo, 740
Rawlins, M. D., *see* Wynne, 297
Read, S. E., *see* Heathcote, 105
Renaud, G., Hamilton, R. L. and Havel, R. J. Hepatic metabolism of colloidal gold-low-density lipoprotein complexes in the rat: Evidence for bulk excretion of lysosomal contents into bile, 380
Renner, E. L., *see* Frey, 606
Rey, C., *see* Chazouillères, 824
Rey, C., *see* Marteau, 820
Reynolds, R. C., *see* Berger, 219
Reynolds, T. B., *see* Fong, 423
Riedel, A., *see* Gerbes, 417
Roberts, S., *see* Lombard, 1
Rocheleau, B., *see* Mastai, 265
Rodés, J., *see* Kravetz, 808
Rodés, J., *see* Lozano, 911
Rojkind, M., *see* Annoni, 693
Rojkind, M., *see* Kershenobich, 656
Roth, E., *see* Zimmermann, 594
Ruebner B., *see* Krams, 411
Runyon, B. A., *see* Fong, 423
Runyon, B. A. Correspondence: Reply, 662

Saba, T. M., *see* Vincent, 562
Saffari-Fard, A., *see* Jennett, 57
Saibara, T., Onishi, S., Sakaeda, H. and Yamamoto, Y. Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma, 471
Sainz, S., Soriano, G., Guarner, C., Coll, P. and Vilardell, F. Correspondence: To the Editor—More on ascitic fluid culture technique, 662
Saito, I., *see* Onji, 92
Sakaeda, H., *see* Saibara, 471
Sakiyama, O., *see* Tsubouchi, 875
Sakurai, A., *see* Tarao, 589
Salzer, M., *see* Just, 570
Sangiovanni, A., *see* Colombo, 433
Santi, V., *see* Gaiani, 815
Sarrión, J. V., *see* Hoyos, 449
Sauerbruch, T., *see* Gerbes, 417
Sauerbruch, T. HEPATOLOGY *Elsewhere*—What is the place of laser lithotripsy in the treatment of common bile duct stones?, 792
Schaad, H. J., *see* Frey, 606
Schaffner, F., *see* Bach, 698
Scharschmidt, B. F. and Lake, J. R. HEPATOLOGY *Elsewhere*—Impaired sulfoxidation in patients with primary biliary cirrhosis, 654
Schenker, S., *see* Schmid, 669
Scheuer, P. J., *see* Karayiannis, 186
Schiaffonati, L., *see* Cairo, 740
Schimassek, H., *see* Just, 570
Schmid, R. and Schenker, S. Editorial—Hans Popper in Memoriam 1903–1988, 669
Schmucker, D. L., *see* Daniels, 229
Schoen, R. T. HEPATOLOGY *Elsewhere*—Relapsing or reinfectious Lyme hepatitis, 335
Schrier, R. W. Correspondence: Reply, 798
Schriever, C. E. and Jüngst, D. Association between cholesterol-phospholipid vesicles and cholesterol crystals in human gallbladder bile, 541
Schulte-Hermann, R., *see* Bursch, 830
Schwab, A. J., *see* St-Pierre, 285
Scott, S. S., *see* Henderson, 582
Seeff, L. B., *see* Lewis, 679
Senaldi, G., Mieli-Vergani, G., Mowat, A. P. and Vergani, D. Correspondence: To the Editor—C4 function in children with autoimmune chronic active hepatitis, 345
Serrano, M., *see* Prieto, 720
Shabot, J. M. HEPATOLOGY *Elsewhere—Chlamydia trachomatis* and ascites: Going with the flow?, 505
Shanahan, M., *see* Hardison, 866
Sheen, I-S. and Liaw, Y-F. The prevalence and incidence of cholecystolithiasis in patients with chronic liver disease: A prospective study, 538
Sherman, M. Correspondence: To the Editor—Complexities of HBA DNA integration, 514
Sheu, J-C., *see* Hsu, 747
Shindo, M., Okuno, T., Arai, K., Matsumoto, M., Takeda, M., Takino, T. and Sokawa, Y. Elevated levels of 2′,5′-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B, 715
Shneider, B., *see* Whitington, 393
Shouval, D., *see* Takahashi, 625
Sicot, C., *see* Moreau, 427
Simon, F. R., *see* d'Arville, 6
Sirica, A. E., *see* Mathis, 477
Smadja, C., *see* Kemeny, 253
Snodgrass, P. J. Urea cycle enzyme activities are normal and inducible by a high-protein diet in CCl_4 cirrhosis of rats, 373
Snover, D. C., Weisdorf, S., Bloomer, J., McGlave, P. and Weisdorf, D. Nodular regenerative hyperplasia of the liver following bone marrow transplantation, 443
Sokawa, Y., *see* Shindo, 715
Sokol, R. J. Editorial—The coming of age of vitamin E, 649
Somer, M. P., *see* Bursch, 830
Soriano, G., *see* Sainz, 662
Sorrell, M. F., *see* Jennett, 57
Specker, B., *see* Heubi, 258
Spero, J. A., *see* Lewis, 710
Springolo, E., Kew, M. C., Esser, J., Beyers, M., Conradie, J. D. and Levin, J. The use of a monoclonal antibody against α-fetoprotein for the radioimmunodetection of hepatocellular carcinoma, 116
Starzl, T. E., *see* Francavilla, 614
Starzl, T. E., *see* Lewis, 710
Starzl, T. E., *see* Oguma, 204
Stefanini, S., *see* Hassan, 37
Steffan, A.-M., *see* Chen, 352
Stellaard, F., *see* Pauletzki, 852
Stock, R. J., Cilento, E. V. and McCuskey, R. S. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver, 75
St-Pierre, M. V., Schwab, A. J., Goresky, C. A., Lee, W.-F. and Pang, K. S. The multiple-indicator dilution technique for characterization of normal and retrograde flow in once-through rat liver perfusions, 285
Straka, J. G., *see* Kools, 557
Strauss, W., *see* Takahashi, 625
Su, T.-S., Lui, W.-Y., Lin, L.-H., Han, S.-H. and P'eng, F.-K. Analysis of hepatitis B virus transcripts in infected human livers, 180
Subirá, M-L., *see* Prieto, 720
Sugihara, J., *see* Tsubouchi, 875
Sugimachi, K., *see* Matsumata, 457
Sujita, K., *see* Arai, 846
Sundheimer, J. E., *see* Yang, 363
Surh, C. D., Danner, D. J., Ahmed, A., Coppel, R. L., Mackay, I. R., Dickson, E. R. and Gershwin, M. E. Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain α-keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen, 63
Surh, C. D., *see* Krams, 411

Tacchini, L., *see* Cairo, 740
Takada, A., *see* Takase, 704
Takagi, S., *see* Tarao, 589
Takahashi, H., Ozturk, M., Wilson, B., Maki, A., Ozawa, K., Koizumi, M., Endo, K., Strauss, W., Shouval, D. and Wands, J. *In vivo* expression of two novel tumor-associated antigens and their use in immunolocalization of human hepatocellular carcinoma, 625
Takahashi, K., *see* Tsubouchi, 875
Takase, S., Takada, A., Yasuhara, M. and Tsutsumi, M. Hepatic aldehyde dehydrogenase activity in liver diseases, with particular emphasis on alcoholic liver disease, 704
Takeda, M., *see* Shindo, 715
Takenaka, K., *see* Matsumata, 457
Takino, T., *see* Shindo, 715
Tamai, S., *see* Tarao, 589
Tamayo, R. P., *see* Kershenobich, 656
Taper, H. S., *see* Bursch, 830
Tarao, K., Hoshino, H., Motohashi, I., Iimori, K., Tamai, S., Ito, Y., Takagi, S., Oikawa, Y., Unayama, S., Fujiwara, T., Odagiri, K., Ikeda, T., Hayashi, K., Sakurai, A. and Uchikoshi, T. Changes in liver and spleen volume in alcoholic liver fibrosis of man, 589
Taylor, J. M., *see* Mason, 635
Templin, D. W., *see* McMahon, 97
Tennant, B. C., *see* Korba, 461
Terblanche, J., *see* Oakland, 602
Thiele, D. L. Editorial—Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease, 497
Thomas, H. C., *see* Karayiannis, 186
Thomas, H. C., *see* Onji, 92
Thorgeirsson, S. S., *see* Huber, 756
Thornton, J. R. and Losowsky, M. S. Correspondence: To the Editor—Does vasodilatation promote ascites formation and portal hypertension?, 797
Thung, S. N., *see* Gerber, 328
Thung, S. N., Wang, D-F., Fasy, T. M., Hood, A. and Gerber, M. A. Hepatitis B surface antigen binds to human serum albumin cross-linked by transglutaminase, 726
Thung, S. N. Book Review, 795
Tiniakos, D., *see* Burt, 839
Tomita, E., *see* Tsubouchi, 875
Tommasini, M., *see* Colombo, 433
Trevisani, F., Bernardi, M. and Gasbarrini, G. Correspondence: To the Editor— Gluconeogenesis from nitrogen precursors and hyperammonemia of cirrhosis: Is there a cause-effect relationship?, 343
Tsai, Y.-T., *see* Lee, 102
Tsang, R. C., *see* Heubi, 258
Tsubouchi, H., Hirono, S., Gohda, E., Nakayama, H., Takahashi, K., Sakiyama, O., Miyazaki, H., Sugihara, J., Tomita, E., Muto, Y., Daikuhara, Y. and Hashimoto, S. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure, 875
Tsuchiya, M., *see* Arai, 846
Tsukamoto, H. and Xi, X. P. Incomplete compensation of enhanced hepatic oxygen consumption in rats with alcoholic centrilobular liver necrosis, 302
Tsutsumi, M., *see* Takase, 704
Tuma, D. J., *see* Jennett, 57

Uchikoshi, T., *see* Tarao, 589
Unayama, S., *see* Tarao, 589
Urban, E., Dindzans, V. J. and Van Thiel, D. H. HEPATOLOGY *Elsewhere*—Hyperparathyroidism and portacaval shunt: A syndrome or a coincidence?, 506

Vadrot, J., *see* Kemeny, 253
Vakil, N., Abu-Alfa, A. and Mujais, S. K. Gentamicin nephrotoxicity in extrahepatic cholestasis: Modulation by dietary calcium, 519
Van Steenbergen, W., Fevery, J., De Vos, R., Leyten, R., Heirwegh, K. P. M. and De Groote, J. Thyroid hormones and the hepatic handling of bilirubin. I. Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat, 314
Van Thiel, D. H., *see* Urban, 506
Van Thiel, D. H. and Gavaler, J. S. HEPATOLOGY *Elsewhere*—Prostatic hypertrophy in the elderly cirrhotic patient: An estrogenic or androgenic response?, 167
Vargas, F., *see* Kershenobich, 656
Vergani, D., *see* Lobo-Yeo, 210
Vergani, D., *see* Mieli-Vergani, 198
Vergani, D., *see* Senaldi, 345
Vermeulen, J. L. M., *see* Moorman, 367
Vestal, R. E. Editorial—Aging and determinants of hepatic drug clearance, 331
Vidal-Vanaclocha, F., *see* Barberá-Guillem, 29
Vilardell, F., *see* Sainz, 662
Villavicencio, R., *see* Vorobioff, 88
Vincent, P. A., Cho, E. and Saba, T. M. Effect of repetitive low-dose endotoxin on liver parenchymal and Kupffer cell fibronectin release, 562
Vinel, J.-P., *see* Calès, 439
Vives, J., *see* Lozano, 911
Vonk, R. J., *see* Bijleveld, 532
Vorobioff, J., Garcia-Tsao, G., Groszmann, R., Aceves, G., Picabea, E., Villavicencio, R. and Hernandez-Ortiz, J. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients, 88

Wada, K., *see* Kondo, 751
Walls, S. A., *see* Mathis, 477
Wands, J., *see* Takahashi, 625
Wang, D-F., *see* Thung, 726
War[illegible]n, K. W. Book Review, 169
Weisdorf, D., *see* Snover, 443
Weisdorf, S., *see* Snover, 443
Weisfuse, I. B., Hadler, S. C., Fields, H. A., Alter, M. J., O'Malley, P. M., Judson, F. N., Ostrow, D. G. and Altman, N. L. Delta hepatitis in homosexual men in the United States, 872
Wells, F. V., *see* Korba, 461
Wernze, H., *see* Gerbes, 417
West, A. B. Book Review, 659
Westaby, D,. Hayes, P. C., Gimson, A. E. S., Polson, R. J. and Williams, R. Controlled clinical trial of injection sclerotherapy for active variceal bleeding, 274
Whitington, P. F., Kehrer, B. H., Whitington, S. H., Shneider, B. and Black, D. D. The effect of biliary enteroenterostomy on the pharmacokinetics of enterally administered cyclosporine in rats, 393
Whitington, S. H., *see* Whitington, 393
Whitmer, D. I., *see* Kools, 557
Wiesner, R. H., *see* Ludwig, 215
Williams, R., *see* Lombard, 1
Williams, R., *see* Westaby, 274
Wilson, B., *see* Takahashi, 625
Wisebord, S., *see* Erdstein, 621
Wisse, E., *see* Burt, 839
Woodhouse, K. W., *see* Wynne, 297
Wright, T. L. HEPATOLOGY *Elsewhere*—Targeted therapy for hepatic cancer: Good in theory, problematic in practice, 657
Wu, A., *see* Kemeny, 253
Wu, C-Y., *see* Hsu, 747
Wu, G. Y., *see* Keegan-Rogers, 646
Wu, J.-C., *see* Lee, 102
Wu, T.-C., *see* Lee, 102

Wu, T-T., *see* Hsu, 747
Wynne, H. A., Cope, L. H., Mutch, E., Rawlins, M. D., Woodhouse, K. W. and James, O. F. W. The effect of age upon liver volume and apparent liver blood flow in healthy man, 297

Xi, X. P., *see* Tsukamoto, 302

Yamaguchi, Y., Bollinger, R. R., DeFaria, E., Landis, B. and Quarfordt, S. A simplified single stage total hepatectomy in the rat with maintenance of gastrointestinal absorptive function, 69
Yamamoto, Y., *see* Saibara, 471
Yang, S.-S., Korula, J., Sundheimer, J. E. and Keyser, A. J. Digoxin-like immunoreactive substances in chronic liver disease, 363
Yasuhara, M., *see* Takase, 704
Yim, C. K., *see* Heathcote, 105
Yoshida, Y., *see* Matsumata, 457
Yurdaydin, C., *see* Zimmermann, 594

Zieve, L. Book Review, 905
Zimmerman, H. J., *see* Lewis, 679
Zimmermann, C., Ferenci, P., Pifl, C., Yurdaydin, C., Ebner, J., Lassmann, H., Roth, E. and Hörtnagl, H. Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: Characterization of an improved model and study of amino acid-ergic neurotransmission, 594
Zironi, G., *see* Gaiani, 815